Examination Guidelines Update: Developments in the Obviousness Inquiry After KSR v.Teleflex, 53643-53660 [2010-21646]
Download as PDF
53643
hsrobinson on DSK69SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
(8) Narrow woven ribbons comprised
at least 85 percent by weight of threads
having a denier of 225 or higher;
(9) Narrow woven ribbons constructed
from pile fabrics (i.e., fabrics with a
surface effect formed by tufts or loops of
yarn that stand up from the body of the
fabric);
(10) Narrow woven ribbon affixed
(including by tying) as a decorative
detail to non-subject merchandise, such
as a gift bag, gift box, gift tin, greeting
card or plush toy, or affixed (including
by tying) as a decorative detail to
packaging containing non-subject
merchandise;
(11) Narrow woven ribbon that is (a)
affixed to non-subject merchandise as a
working component of such non-subject
merchandise, such as where narrow
woven ribbon comprises an apparel
trimming, book marker, bag cinch, or
part of an identity card holder, or (b)
affixed (including by tying) to nonsubject merchandise as a working
component that holds or packages such
non-subject merchandise or attaches
packaging or labeling to such nonsubject merchandise, such as a ‘‘belly
band’’ around a pair of pajamas, a pair
of socks or a blanket;
(12) Narrow woven ribbon(s)
comprising a belt attached to and
imported with an item of wearing
apparel, whether or not such belt is
removable from such item of wearing
apparel; and
(13) Narrow woven ribbon(s) included
with non-subject merchandise in kits,
such as a holiday ornament craft kit or
a scrapbook kit, in which the individual
lengths of narrow woven ribbon(s)
included in the kit are each no greater
than eight inches, the aggregate amount
of narrow woven ribbon(s) included in
the kit does not exceed 48 linear inches,
none of the narrow woven ribbon(s)
included in the kit is on a spool, and the
narrow woven ribbon(s) is only one of
multiple items included in the kit.
The merchandise subject to this order
is classifiable under the HTSUS
statistical categories 5806.32.1020;
5806.32.1030; 5806.32.1050 and
5806.32.1060. Subject merchandise also
may enter under subheadings
5806.31.00; 5806.32.20; 5806.39.20;
5806.39.30; 5808.90.00; 5810.91.00;
5810.99.90; 5903.90.10; 5903.90.25;
5907.00.60; and 5907.00.80 and under
statistical categories 5806.32.1080;
5810.92.9080; 5903.90.3090; and
6307.90.9889. The HTSUS statistical
categories and subheadings are provided
for convenience and customs purposes;
however, the written description of the
merchandise under the order is
dispositive.
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
Countervailing Duty Order
According to section 706(b)(2) of the
Act, duties shall be assessed on subject
merchandise entered, or withdrawn
from warehouse, for consumption on or
after the date of publication of the ITC’s
notice of final determination if that
determination is based upon the threat
of material injury. Section 706(b)(1) of
the Act states, ‘‘If the Commission, in its
final determination under section
705(b), finds material injury or threat of
material injury which, but for the
suspension of liquidation under section
703(d)(2), would have led to a finding
of material injury, then entries of the
merchandise subject to the
countervailing duty order, the
liquidation of which has been
suspended under section 703(d)(2),
shall be subject to the imposition of
countervailing duties under section
701(a).’’ In addition, section 706(b)(2) of
the Act requires CBP to refund any cash
deposits or bonds of estimated
countervailing duties posted since the
Department’s preliminary
countervailing duty determination, if
the ITC’s final determination is threatbased. Because the ITC’s final
determination in this case is based on
the threat of material injury and is not
accompanied by a finding that injury
would have resulted but for the
imposition of suspension of liquidation
of entries since the Department’s
Preliminary Determination 1 was
published in the Federal Register,
section 706(b)(2) of the Act is
applicable.
As a result of the ITC’s determination,
and in accordance with section 706(a)(1)
of the Act, the Department will direct
U.S. Customs and Border Protection
(‘‘CBP’’) to assess, upon further
instruction by the Department,
countervailing duties equal to the
amount of the net countervailable
subsidy for all relevant entries of narrow
woven ribbons from the PRC. In
accordance with section 706 of the Act,
the Department will direct CBP to
reinstitute suspension of liquidation 2
effective on the date of publication of
the ITC’s notice of final determination
in the Federal Register, and to require
a cash deposit for each entry of subject
1 Narrow Woven Ribbons With Woven Selvedge
From the People’s Republic of China: Preliminary
Affirmative Countervailing Duty Determination and
Alignment of Final Countervailing Duty
Determination With Final Antidumping Duty
Determination, 74 FR 66090 (December 14, 2009).
2 The Department instructed CBP to discontinue
the suspension of liquidation on April 13, 2010, in
accordance with section 703(d) of the Act. Section
703(d) states that the suspension of liquidation
pursuant to a preliminary determination may not
remain in effect for more than four months.
PO 00000
Frm 00014
Fmt 4703
Sfmt 4703
merchandise in an amount equal to the
net countervailable subsidy rates noted
below.
Exporter/manufacturer
Net subsidy
rate
Yama Ribbons and Bows Co.,
Ltd .........................................
Changtai Rongshu Textile Co.,
Ltd .........................................
All Others ..................................
1.56
117.95
1.56
Termination of the Suspension of
Liquidation
The Department will also instruct
CBP to terminate the suspension of
liquidation for entries of narrow woven
ribbons from the PRC entered, or
withdrawn from warehouse, for
consumption prior to the publication of
the ITC’s notice of final determination,
and refund any cash deposits made and
release any bonds posted between
December 14, 2009 (i.e., the date of
publication of the Department’s
Preliminary Determination) and the date
of publication of the ITC’s final
determination in the Federal Register.
This notice constitutes the
countervailing duty order with respect
to narrow woven ribbons from the PRC,
pursuant to section 706(a) of the Act.
Interested parties may contact the
Department’s Central Records Unit,
Room 1117 of the main Commerce
Building, for copies of an updated list
of countervailing duty orders currently
in effect.
This order is issued and published in
accordance with section 706(a) of the
Act and 19 CFR 351.211(b).
Dated: August 30, 2010.
Ronald K. Lorentzen,
Deputy Assistant Secretary for Import
Administration.
[FR Doc. 2010–21978 Filed 8–31–10; 8:45 am]
BILLING CODE 3510–DS–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No.: PTO–P–2010–0055]
Examination Guidelines Update:
Developments in the Obviousness
Inquiry After KSR v.Teleflex
United States Patent and
Trademark Office, Commerce.
ACTION: Notice.
AGENCY:
The United States Patent and
Trademark Office (USPTO or Office) is
issuing an update (2010 KSR Guidelines
Update) to its obviousness guidelines
for its personnel to be used when
applying the law of obviousness under
SUMMARY:
E:\FR\FM\01SEN1.SGM
01SEN1
hsrobinson on DSK69SOYB1PROD with NOTICES
53644
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
35 U.S.C. 103. This 2010 KSR
Guidelines Update highlights case law
developments on obviousness under 35
U.S.C. 103 since the 2007 decision by
the United States Supreme Court
(Supreme Court) in KSR Int’l Co. v.
Teleflex Inc. These guidelines are
intended to be used by Office personnel
in conjunction with the guidance in the
Manual of Patent Examining Procedure
when applying the law of obviousness
under 35 U.S.C. 103. Members of the
public are invited to provide comments
on the 2010 KSR Guidelines Update.
The Office is especially interested in
receiving suggestions of recent
decisional law in the field of
obviousness that would have particular
value as teaching tools.
DATES: Effective Date: This 2010 KSR
Guidelines Update is effective
September 1, 2010.
ADDRESSES: Comments concerning this
2010 KSR Guidelines Update may be
sent by electronic mail message over the
Internet addressed to
KSR_Guidance@uspto.gov, or submitted
by mail addressed to: Mail Stop
Comments—Patents, Commissioner for
Patents, P.O. Box 1450, Alexandria, VA
22313–1450. Although comments may
be submitted by mail, the Office prefers
to receive comments via the Internet.
FOR FURTHER INFORMATION CONTACT:
Kathleen Kahler Fonda or Pinchus M.
Laufer, Legal Advisors, Office of Patent
Legal Administration, Office of the
Associate Commissioner for Patent
Examination Policy, by telephone at
(571) 272–7754 or (571) 272–7726; by
mail addressed to: Mail Stop Comments
Patents, Commissioner for Patents, P.O.
Box 1450, Alexandria, VA 22313–1450;
or by facsimile transmission to (571)
273–7754, marked to the attention of
Kathleen Kahler Fonda.
SUPPLEMENTARY INFORMATION:
1. Introduction. The purpose of this
2010 KSR Guidelines Update is to
remind Office personnel of the
principles of obviousness explained by
the Supreme Court in KSR Int’l Co. v.
Teleflex Inc., 550 U.S 398 (2007) (KSR),
and to provide additional guidance in
view of decisions by the United States
Court of Appeals for the Federal Circuit
(Federal Circuit) since KSR. This body
of case law developed over the past
three years provides additional
examples that will be useful to Office
personnel as well as practitioners
during the examination process.
Although every question of obviousness
must be decided on its own facts, these
cases begin to clarify the contours of the
obviousness inquiry after KSR, and help
to show when a rejection on this basis
is proper and when it is not.
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
This 2010 KSR Guidelines Update
does not constitute substantive rule
making and hence does not have the
force and effect of law. It has been
developed as a matter of internal Office
management and is not intended to
create any right or benefit, substantive
or procedural, enforceable by any party
against the Office. Rejections will
continue to be based upon the
substantive law, and it is these
rejections that are appealable.
Consequently, any failure by Office
personnel to follow this 2010 KSR
Guidelines Update is neither appealable
nor petitionable.
After a review of the principles of
obviousness and Office policy as
reflected in the Manual of Patent
Examining Procedure (MPEP), this 2010
KSR Guidelines Update addresses a
number of issues that arise when Office
personnel consider whether or not a
claimed invention is obvious. The
concepts discussed are grounded in
Federal Circuit cases, and correlated
with existing Office policy as
appropriate. A number of cases which
have been selected for their
instructional value on the issue of
obviousness will be discussed in detail.
The law of obviousness will continue
to be refined, and Office personnel are
encouraged to maintain an awareness of
precedential case law from the Federal
Circuit and precedential decisions of the
Board of Patent Appeals and
Interferences (Board) in this area. The
Office will train Office personnel and
update the MPEP as necessary to reflect
the current state of the law.
2. Principles of Obviousness and the
Guidelines. In response to the Supreme
Court’s April 2007 decision in KSR, the
Office developed guidelines for patent
examiners to follow when determining
obviousness of a claimed invention and
published these guidelines in the
Federal Register and Official Gazette.
See Examination Guidelines for
Determining Obviousness Under 35
U.S.C. 103 in View of the Supreme
Court Decision in KSR International Co.
v. Teleflex Inc., 72 FR 57526 (Oct. 10,
2007), 1324 Off. Gaz. Pat. Office 23
(Nov. 6, 2007) (2007 KSR Guidelines).
The 2007 KSR Guidelines have been
incorporated in the MPEP. See MPEP
§ 2141 (8th ed. 2001) (Rev. 6, Sept.
2007). The purpose of the 2007 KSR
Guidelines was to give Office personnel
practical guidance on how to evaluate
obviousness issues under 35 U.S.C.
103(a) in accordance with the Supreme
Court’s instruction in KSR. The 2007
KSR Guidelines also alerted Office
personnel to the importance of
considering rebuttal evidence submitted
PO 00000
Frm 00015
Fmt 4703
Sfmt 4703
by patent applicants in response to
obviousness rejections.
The 2007 KSR Guidelines pointed out,
as had the Supreme Court in KSR, that
the factual inquiries announced in
Graham v. John Deere, 383 U.S. 1, 17–
18 (1966) (scope and content of the prior
art; differences between the claimed
invention and the prior art; level of
ordinary skill in the art; and secondary
indicia of nonobviousness), remain the
foundation of any determination of
obviousness. It remains true that ‘‘[t]he
determination of obviousness is
dependent on the facts of each case.’’
Sanofi-Synthelabo v. Apotex, Inc., 550
F.3d 1075, 1089 (Fed. Cir. 2008) (citing
Graham, 383 U.S. at 17–18 (1966)). As
for the reasoning required to support an
obviousness determination, the 2007
KSR Guidelines noted that the teachingsuggestion-motivation (TSM) test was
but one possible approach. The 2007
KSR Guidelines identified six other
rationales gleaned from the KSR
decision as examples of appropriate
lines of reasoning that could also be
used. The six other rationales identified
in the 2007 KSR Guidelines are: (1)
Combining prior art elements according
to known methods to yield predictable
results; (2) simple substitution of one
known element for another to obtain
predictable results; (3) use of a known
technique to improve similar devices,
methods, or products in the same way;
(4) applying a known technique to a
known device, method, or product
ready for improvement to yield
predictable results; (5) obvious to try—
choosing from a finite number of
identified, predictable solutions, with a
reasonable expectation of success; and
(6) known work in one field of endeavor
may prompt variations of it for use in
either the same field or a different one
based on design incentives or other
market forces if the variations are
predictable to one of ordinary skill in
the art. Any rationale employed must
provide a link between the factual
findings and the legal conclusion of
obviousness.
It is important for Office personnel to
recognize that when they do choose to
formulate an obviousness rejection
using one of the rationales suggested by
the Supreme Court in KSR and
discussed in the 2007 KSR Guidelines,
they are to adhere to the instructions
provided in the MPEP regarding the
necessary factual findings. However, the
2007 KSR Guidelines also stressed that
while the Graham inquiries and the
associated reasoning are crucial to a
proper obviousness determination, the
Supreme Court in KSR did not place any
limit on the particular approach to be
taken to formulate the line of reasoning.
E:\FR\FM\01SEN1.SGM
01SEN1
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
In other words, the KSR decision is not
to be seen as replacing a single test for
obviousness—the TSM test—with the
seven rationales listed in the 2007 KSR
Guidelines. See MPEP §§ 2141 and 2143
(8th ed. 2001) (Rev. 8, July 2010)
(references to the MPEP are to Revision
8 of the 8th Edition of the MPEP unless
otherwise indicated). It remains Office
policy that appropriate factual findings
are required in order to apply the
enumerated rationales properly. If a
rejection has been made that omits one
of the required factual findings, and in
response to the rejection a practitioner
or inventor points out the omission,
Office personnel must either withdraw
the rejection, or repeat the rejection
including all required factual findings.
3. The Impact of the KSR Decision.
KSR’s renewed emphasis on the
foundational principles of Graham
coupled with its abrogation of the strict
TSM test have clearly impacted the
manner in which Office personnel and
practitioners carry out the business of
prosecuting patent applications with
regard to issues of obviousness.
However, Office personnel as well as
practitioners should also recognize the
significant extent to which the
obviousness inquiry has remained
constant in the aftermath of KSR.
In footnote 2 of the 2007 KSR
Guidelines, the Office acknowledged
that ongoing developments in the law of
obviousness were to be expected in the
wake of the KSR decision. That footnote
also stated that it was ‘‘not clear which
Federal Circuit decisions will retain
their viability’’ after KSR. See 2007 KSR
Guidelines, 72 FR at 57,528 n.2. The
edition of the MPEP that was current
when the KSR decision was handed
down had made the following statement
in § 2144:
hsrobinson on DSK69SOYB1PROD with NOTICES
The rationale to modify or combine the
prior art does not have to be expressly stated
in the prior art; the rationale may be
expressly or impliedly contained in the prior
art or it may be reasoned from knowledge
generally available to one of ordinary skill in
the art, established scientific principles, or
legal precedent established by prior case law.
MPEP § 2144 (8th ed. 2001) (Rev. 5,
Aug. 2006) (citing five pre-KSR Federal
Circuit opinions and two decisions of
the Board). The KSR decision has
reinforced those earlier decisions that
validated a more flexible approach to
providing reasons for obviousness.
However, the Supreme Court’s
pronouncement in KSR has at the same
time clearly undermined the continued
viability of cases such as In re Lee, 277
F.3d 1338 (Fed. Cir. 2002), insofar as
Lee appears to require a strict basis in
record evidence as a reason to modify
the prior art.
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
The Supreme Court’s flexible
approach to the obviousness inquiry is
reflected in numerous pre-KSR
decisions, as can be seen in a review of
MPEP § 2144. This section provides
many lines of reasoning to support a
determination of obviousness based
upon earlier legal precedent that had
condoned the use of particular examples
of what may be considered common
sense or ordinary routine practice (e.g.,
making integral, changes in shape,
making adjustable). Thus, the type of
reasoning sanctioned by the opinion in
KSR has long been a part of the patent
examination process. See MPEP § 2144.
Although the KSR approach is flexible
with regard to the line of reasoning to
be applied, the 2007 KSR Guidelines
and MPEP § 2143 state: ‘‘The Supreme
Court in KSR noted that the analysis
supporting a rejection under 35 U.S.C.
103 should be made explicit.’’ MPEP
§ 2143. In Ball Aerosol v. Limited
Brands, 555 F.3d 984 (Fed. Cir. 2009),
the Federal Circuit offered additional
instruction as to the need for an explicit
analysis. The Federal Circuit explained,
as is consistent with the 2007 KSR
Guidelines, that the Supreme Court’s
requirement for an explicit analysis
does not require record evidence of an
explicit teaching of a motivation to
combine in the prior art.
[T]he analysis that ‘‘should be made
explicit’’ refers not to the teachings in the
prior art of a motivation to combine, but to
the court’s analysis * * *. Under the flexible
inquiry set forth by the Supreme Court, the
district court therefore erred by failing to take
account of ‘‘the inferences and creative
steps,’’ or even routine steps, that an inventor
would employ and by failing to find a
motivation to combine related pieces from
the prior art.
Ball Aerosol, 555 F.3d at 993. The
Federal Circuit’s directive in Ball
Aerosol was addressed to a lower court,
but it applies to Office personnel as
well. When setting forth a rejection,
Office personnel are to continue to make
appropriate findings of fact as explained
in MPEP §§ 2141 and 2143, and must
provide a reasoned explanation as to
why the invention as claimed would
have been obvious to a person of
ordinary skill in the art at the time of
the invention. This requirement for
explanation remains even in situations
in which Office personnel may properly
rely on intangible realities such as
common sense and ordinary ingenuity.
When considering obviousness, Office
personnel are cautioned against treating
any line of reasoning as a per se rule.
MPEP § 2144 discusses supporting a
rejection under 35 U.S.C. 103 by
reliance on scientific theory and legal
precedent. In keeping with the flexible
PO 00000
Frm 00016
Fmt 4703
Sfmt 4703
53645
approach and the requirement for
explanation, Office personnel may
invoke legal precedent as a source of
supporting rationale when warranted
and appropriately supported. See MPEP
§ 2144.04. So, for example, automating a
manual activity, making portable,
making separable, reversal or
duplication of parts, or purifying an old
product may form the basis of a
rejection. However, such rationales
should not be treated as per se rules, but
rather must be explained and shown to
apply to the facts at hand. A similar
caveat applies to any obviousness
analysis. Simply stating the principle
(e.g., ‘‘art recognized equivalent,’’
‘‘structural similarity’’) without
providing an explanation of its
applicability to the facts of the case at
hand is generally not sufficient to
establish a prima facie case of
obviousness.
Many basic approaches that a
practitioner may use to demonstrate
nonobviousness also continue to apply
in the post-KSR era. Since it is now
clear that a strict TSM approach is not
the only way to establish a prima facie
case of obviousness, it is true that
practitioners have been required to shift
the emphasis of their nonobviousness
arguments to a certain degree. However,
familiar lines of argument still apply,
including teaching away from the
claimed invention by the prior art, lack
of a reasonable expectation of success,
and unexpected results. Indeed, they
may have even taken on added
importance in view of the recognition in
KSR of a variety of possible rationales.
At the time the KSR decision was
handed down, some observers
questioned whether the principles
discussed were intended by the
Supreme Court to apply to all fields of
inventive endeavor. Arguments were
made that because the technology at
issue in KSR involved the relatively
well-developed and predictable field of
vehicle pedal assemblies, the decision
was relevant only to such fields. The
Federal Circuit has soundly repudiated
such a notion, stating that KSR applies
across technologies:
This court also declines to cabin KSR to the
‘‘predictable arts’’ (as opposed to the
‘‘unpredictable art’’ of biotechnology). In fact,
this record shows that one of skill in this
advanced art would find these claimed
‘‘results’’ profoundly ‘‘predictable.’’
In re Kubin, 561 F.3d 1351, 1360 (Fed.
Cir. 2009). Thus, Office personnel
should not withdraw any rejection
solely on the basis that the invention
lies in a technological area ordinarily
considered to be unpredictable.
The decisions of the Federal Circuit
discussed in this 2010 KSR Guidelines
E:\FR\FM\01SEN1.SGM
01SEN1
hsrobinson on DSK69SOYB1PROD with NOTICES
53646
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
Update provide Office personnel as well
as practitioners with additional
examples of the law of obviousness. The
purpose of the 2007 KSR Guidelines
was, as stated above, to help Office
personnel to determine when a claimed
invention is not obvious, and to provide
an appropriate supporting rationale
when an obviousness rejection is
appropriate. Now that a body of case
law is available to guide Office
personnel and practitioners as to the
boundaries between obviousness and
nonobviousness, it is possible in this
2010 KSR Guidelines Update to contrast
situations in which the subject matter
was found to have been obvious with
those in which it was determined not to
have been obvious. Thus, Office
personnel may use this 2010 KSR
Guidelines Update in conjunction with
the 2007 KSR Guidelines (incorporated
into MPEP §§ 2141 and 2143) to provide
a more complete view of the state of the
law of obviousness.
This 2010 KSR Guidelines Update
provides a ‘‘teaching point’’ for each
discussed case. The ‘‘teaching point’’
may be used to quickly determine the
relevance of the discussed case, but
should not be used as a substitute for
reading the remainder of the discussion
of the case in this 2010 KSR Guidelines
Update. Nor should any case in this
2010 KSR Guidelines Update be applied
or cited in an Office action solely on the
basis of what is stated in the ‘‘teaching
point’’ for the case.
4. Obviousness Examples from
Federal Circuit Cases. The impact of the
Supreme Court’s decision in KSR can be
more readily understood in the context
of factual scenarios. The cases in this
2010 KSR Guidelines Update are
broadly grouped according to
obviousness concepts in order to
provide persons involved with patent
prosecution with ready access to the
examples that are most pertinent to the
issue at hand. The first three groups
correspond directly with three of the
rationales identified in the 2007 KSR
Guidelines. These rationales—
combining prior art elements,
substituting one known element for
another, and obvious to try—have each
been the subject of a significant number
of post-KSR obviousness decisions. The
fourth group focuses on issues
concerning consideration of evidence
during prosecution. Office personnel as
well as practitioners are reminded of the
technology-specific obviousness
examples previously posted on the
Office’s Web site at https://
www.uspto.gov/web/offices/pac/dapp/
opla/ksr/ksr_training_materials.htm.
Although the other rationales
discussed in the 2007 KSR Guidelines
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
are not the focus of separate discussions
in this 2010 KSR Guidelines Update, it
will be noted that obviousness concepts
such as applying known techniques,
design choice, and market forces are
addressed when they arise in the
selected cases. The cases included in
this 2010 KSR Guidelines Update
reinforce the idea, presented in the 2007
KSR Guidelines, that there may be more
than one line of reasoning that can
properly be applied to a particular
factual scenario. The selected decisions
also illustrate the overlapping nature of
the lines of reasoning that may be
employed to establish a prima facie case
of obviousness. Although the 2007 KSR
Guidelines presented the rationales as
discrete, self-contained lines of
reasoning, and they may indeed be
employed that way, it is useful to
recognize that real-world situations may
require analyses that may not be so
readily pigeon-holed into distinct
categories.
A. Combining Prior Art Elements. In
discussing the obviousness rationale
concerning combining prior art
elements, identified as Rationale A, the
2007 KSR Guidelines quoted KSR and
noted that ‘‘it can be important to
identify a reason that would have
prompted a person of ordinary skill in
the relevant field to combine the
elements in the way the claimed new
invention does.’’ KSR, 550 U.S. at 401.
In view of the cases decided since KSR,
one situation when it is important to
identify a reason to combine known
elements in a known manner to obtain
predictable results is when the
combination requires a greater
expenditure of time, effort, or resources
than the prior art teachings. Even
though the components are known, the
combining step is technically feasible,
and the result is predictable, the
claimed invention may nevertheless be
nonobvious when the combining step
involves such additional effort that no
one of ordinary skill would have
undertaken it without a recognized
reason to do so. When a combination
invention involves additional
complexity as compared with the prior
art, the invention may be nonobvious
unless an examiner can articulate a
reason for including the added features
or steps. This is so even when the
claimed invention could have been
readily implemented.
Example 4.1. In re Omeprazole Patent
Litigation, 536 F.3d 1361 (Fed. Cir.
2008). Teaching point: Even where a
general method that could have been
applied to make the claimed product
was known and within the level of skill
of the ordinary artisan, the claim may
nevertheless be nonobvious if the
PO 00000
Frm 00017
Fmt 4703
Sfmt 4703
problem which had suggested use of the
method had been previously unknown.
The case of In re Omeprazole Patent
Litigation is one in which the claims in
question were found to be nonobvious
in the context of an argument to
combine prior art elements. The
invention involved applying enteric
coatings to a drug in pill form for the
purpose of ensuring that the drug did
not disintegrate before reaching its
intended site of action. The drug at
issue was omeprazole, the generic name
for gastric acid inhibitor marketed as
Prilosec®. The claimed formulation
included two layers of coatings over the
active ingredient.
The district court found that Astra’s
patent in suit was infringed by
defendants Apotex and Impax. The
district court rejected Apotex’s defense
that the patents were invalid for
obviousness. Apotex had argued that the
claimed invention was obvious because
coated omeprazole tablets were known
from a prior art reference, and because
secondary subcoatings in
pharmaceutical preparations generally
were also known. There was no
evidence of unpredictability associated
with applying two different enteric
coatings to omeprazole. However,
Astra’s reason for applying an
intervening subcoating between the
prior art coating and omeprazole had
been that the prior art coating was
actually interacting with omeprazole,
thereby contributing to undesirable
degradation of the active ingredient.
This degradation of omeprazole by
interaction with the prior art coating
had not been recognized in the prior art.
Therefore, the district court reasoned
that based on the evidence available, a
person of ordinary skill in the art would
have had no reason to include a
subcoating in an omeprazole pill
formulation.
The Federal Circuit affirmed the
district court’s decision that the claimed
invention was not obvious. Even though
subcoatings for enteric drug formulation
were known, and there was no evidence
of undue technical hurdles or lack of a
reasonable expectation of success, the
formulation was nevertheless not
obvious because the flaws in the prior
art formulation that had prompted the
modification had not been recognized.
Thus there would have been no reason
to modify the initial formulation, even
though the modification could have
been done. Moreover, a person of skill
in the art likely would have chosen a
different modification even if he or she
had recognized the problem.
Office personnel should note that in
this case the modification of the prior
art that had been presented as an
E:\FR\FM\01SEN1.SGM
01SEN1
hsrobinson on DSK69SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
argument for obviousness was an extra
process step that added an additional
component to a known, successfully
marketed formulation. The proposed
modification thus amounted to extra
work and greater expense for no
apparent reason. This is not the same as
combining known prior art elements A
and B when each would have been
expected to contribute its own known
properties to the final product. In the
Omeprazole case, in view of the
expectations of those of ordinary skill in
the art, adding the subcoating would not
have been expected to confer any
particular desirable property on the
final product. Rather, the final product
obtained according to the proposed
modifications would merely have been
expected to have the same functional
properties as the prior art product.
The Omeprazole case can also be
analyzed in view of the discovery of a
previously unknown problem by the
patentee. If the adverse interaction
between active agent and coating had
been known, it might well have been
obvious to use a subcoating. However,
since the problem had not been
previously known, there would have
been no reason to incur additional time
and expense to add another layer, even
though the addition would have been
technologically possible. This is true
because the prior art of record failed to
mention any stability problem, despite
the acknowledgment during testimony
at trial that there was a known
theoretical reason that omeprazole
might be subject to degradation in the
presence of the known coating material.
Example 4.2. Crocs, Inc. v. U.S.
International Trade Commission, 598
F.3d 1294 (Fed. Cir. 2010). Teaching
point: A claimed combination of prior
art elements may be nonobvious where
the prior art teaches away from the
claimed combination and the
combination yields more than
predictable results.
The case of Crocs, Inc. v. U.S.
International Trade Commission is a
decision in which the claimed foam
footwear was held by the Federal Circuit
to be nonobvious over a combination of
prior art references.
The claims involved in the
obviousness issue were from Crocs’ U.S.
Patent No. 6,993,858, and were drawn to
footwear in which a one-piece molded
foam base section formed the top of the
shoe (the upper) and the sole. A strap
also made of foam was attached to the
foot opening of the upper, such that the
strap could provide support to the
Achilles portion of the wearer’s foot.
The strap was attached via connectors
that allowed it to be in contact with the
base section, and to pivot relative to the
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
base section. Because both the base
portion and the strap were made of
foam, friction between the strap and the
base section allowed the strap to
maintain its position after pivoting. In
other words, the foam strap did not fall
under the force of gravity to a position
adjacent to the heel of the base section.
The International Trade Commission
(ITC) determined that the claims were
obvious over the combination of two
pieces of prior art. The first was the
Aqua Clog, which was a shoe that
corresponded to the base section of the
footwear of the ‘858 patent. The second
was the Aguerre patent, which taught
heel straps made of elastic or another
flexible material. In the ITC’s view, the
claimed invention was obvious because
the prior art Aqua Clog differed from the
claimed invention only as to the
presence of the strap, and a suitable
strap was taught by Aguerre.
The Federal Circuit disagreed. The
Federal Circuit stated that the prior art
did not teach foam heel straps, or that
a foam heel strap should be placed in
contact with a foam base. The Federal
Circuit pointed out that the prior art
actually counseled against using foam as
a material for the heel strap of a shoe.
The record shows that the prior art would
actually discourage and teach away from the
use of foam straps. An ordinary artisan in
this field would not add a foam strap to the
foam Aqua Clog because foam was likely to
stretch and deform, in addition to causing
discomfort for a wearer. The prior art depicts
foam as unsuitable for straps.
Id. at 1309.
The Federal Circuit continued, stating
that even if—contrary to fact—the
claimed invention had been a
combination of elements that were
known in the prior art, the claims still
would have been nonobvious. There
was testimony in the record that the
loose fit of the heel strap made the shoe
more comfortable for the wearer than
prior art shoes in which the heel strap
was constantly in contact with the
wearer’s foot. In the claimed footwear,
the foam heel strap contacted the
wearer’s foot only when needed to help
reposition the foot properly in the shoe,
thus reducing wearer discomfort that
could arise from constant contact. This
desirable feature was a result of the
friction between the base section and
the strap that kept the strap in place
behind the Achilles portion of the
wearer’s foot. The Federal Circuit
pointed out that this combination
‘‘yielded more than predictable results.’’
Id. at 1310. Aguerre had taught that
friction between the base section and
the strap was a problem rather than an
advantage, and had suggested the use of
nylon washers to reduce friction. Thus
PO 00000
Frm 00018
Fmt 4703
Sfmt 4703
53647
the Federal Circuit stated that even if all
elements of the claimed invention had
been taught by the prior art, the claims
would not have been obvious because
the combination yielded more than
predictable results.
The Federal Circuit’s discussion in
Crocs serves as a reminder to Office
personnel that merely pointing to the
presence of all claim elements in the
prior art is not a complete statement of
a rejection for obviousness. In
accordance with MPEP § 2143 A(3), a
proper rejection based on the rationale
that the claimed invention is a
combination of prior art elements also
includes a finding that results flowing
from the combination would have been
predictable to a person of ordinary skill
in the art. MPEP § 2143 A(3). If results
would not have been predictable, Office
personnel should not enter an
obviousness rejection using the
combination of prior art elements
rationale, and should withdraw such a
rejection if it has been made.
Example 4.3. Sundance, Inc. v.
DeMonte Fabricating Ltd., 550 F.3d
1356 (Fed. Cir. 2008). Teaching point: A
claimed invention is likely to be
obvious if it is a combination of known
prior art elements that would reasonably
have been expected to maintain their
respective properties or functions after
they have been combined.
Sundance involved a segmented and
mechanized cover for trucks, swimming
pools, or other structures. The claim
was found to be obvious over the prior
art applied.
A first prior art reference taught that
a reason for making a segmented cover
was ease of repair, in that a single
damaged segment could be readily
removed and replaced when necessary.
A second prior art reference taught the
advantages of a mechanized cover for
ease of opening. The Federal Circuit
noted that the segmentation aspect of
the first reference and the
mechanization function of the second
perform in the same way after
combination as they had before. The
Federal Circuit further observed that a
person of ordinary skill in the art would
have expected that adding replaceable
segments as taught by the first reference
to the mechanized cover of the other
would result in a cover that maintained
the advantageous properties of both of
the prior art covers.
Thus, the Sundance case points out
that a hallmark of a proper obviousness
rejection based on combining known
prior art elements is that one of ordinary
skill in the art would reasonably have
expected the elements to maintain their
respective properties or functions after
they have been combined.
E:\FR\FM\01SEN1.SGM
01SEN1
hsrobinson on DSK69SOYB1PROD with NOTICES
53648
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
Example 4.4. Ecolab, Inc. v. FMC
Corp., 569 F.3d 1335 (Fed Cir. 2009).
Teaching point: A combination of
known elements would have been
prima facie obvious if an ordinarily
skilled artisan would have recognized
an apparent reason to combine those
elements and would have known how to
do so.
In the case of Ecolab, Inc. v. FMC
Corp., an ‘‘apparent reason to combine’’
in conjunction with the technical ability
to optimize led to the conclusion that
the claimed invention would have been
obvious.
The invention in question was a
method of treating meat to reduce the
incidence of pathogens, by spraying the
meat with an antibacterial solution
under specified conditions. The parties
did not dispute that a single prior art
reference had taught all of the elements
of the claimed invention, except for the
pressure limitation of ‘‘at least 50 psi.’’
FMC had argued at the district court
that the claimed invention would have
been obvious in view of the first prior
art reference mentioned above in view
of a second reference that had taught the
advantages of spray-treating at pressures
of 20 to 150 psi when treating meat with
a different antibacterial agent. The
district court did not find FMC’s
argument to be convincing, and denied
the motion for judgment as a matter of
law that the claim was obvious.
Disagreeing with the district court, the
Federal Circuit stated that ‘‘there was an
apparent reason to combine these
known elements—namely to increase
contact between the [antibacterial
solution] and the bacteria on the meat
surface and to use the pressure to wash
additional bacteria off the meat surface.’’
Id. at 1350. The Federal Circuit
explained that because the second
reference had taught ‘‘using high
pressure to improve the effectiveness of
an antimicrobial solution when sprayed
onto meat, and because an ordinarily
skilled artisan would have recognized
the reasons for applying [the claimed
antibacterial solution] using high
pressure and would have known how to
do so, Ecolab’s claims combining high
pressure with other limitations
disclosed in FMC’s patent are invalid as
obvious.’’ Id.
When considering the question of
obviousness, Office personnel should
keep in mind the capabilities of a
person of ordinary skill. In Ecolab, the
Federal Circuit stated:
Ecolab’s expert admitted that one skilled in
the art would know how to adjust application
parameters to determine the optimum
parameters for a particular solution. The
question then is whether it would have been
obvious to combine the high pressure
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
parameter disclosed in the Bender patent
with the PAA methods disclosed in FMC’s
‘676 patent. The answer is yes.
Id. If optimization of the application
parameters had not been within the
level of ordinary skill in the art, the
outcome of the Ecolab case may well
have been different.
Example 4.5. Wyers v. Master Lock
Co., No. 2009–1412, —F.3d—, 2010 WL
2901839 (Fed. Cir. July 22, 2010).
Teaching point: The scope of analogous
art is to be construed broadly and
includes references that are reasonably
pertinent to the problem that the
inventor was trying to solve. Common
sense may be used to support a legal
conclusion of obviousness so long as it
is explained with sufficient reasoning.
In the case of Wyers v. Master Lock
Co., the Federal Circuit held that the
claimed barbell-shaped hitch pin locks
used to secure trailers to vehicles were
obvious.
The court discussed two different sets
of claims in Wyers, both drawn to
improvements over the prior art hitch
pin locks. The first improvement was a
removable sleeve that could be placed
over the shank of the hitch pin lock so
that the same lock could be used with
towing apertures of varying sizes. The
second improvement was an external
flat flange seal adapted to protect the
internal lock mechanism from
contaminants. Wyers had admitted that
each of several prior art references
taught every element of the claimed
inventions except for the removable
sleeve and the external covering. Master
Lock had argued that these references,
in combination with additional
references teaching the missing
elements, would have rendered the
claims obvious.
The court first addressed the question
of whether the additional references
relied on by Master Lock were
analogous prior art. As to the reference
teaching the sleeve improvement, the
court concluded that it dealt specifically
with using a vehicle to tow a trailer, and
was therefore in the same field of
endeavor as Wyers’ sleeve
improvement. The reference teaching
the sealing improvement dealt with a
padlock rather than a lock for a tow
hitch. The court noted that Wyers’
specification had characterized the
claimed invention as being in the field
of locking devices, thus at least
suggesting that the sealed padlock
reference was in the same field of
endeavor. However, the court also
observed that even if sealed padlocks
were not in the same field of endeavor,
they were nevertheless reasonably
pertinent to the problem of avoiding
contamination of a locking mechanism
PO 00000
Frm 00019
Fmt 4703
Sfmt 4703
for tow hitches. The court explained
that the Supreme Court’s decision in
KSR ‘‘directs [it] to construe the scope of
analogous art broadly.’’ Wyers, slip. op.
at 12. For these reasons, the court found
that Master Lock’s asserted references
were analogous prior art, and therefore
relevant to the obviousness inquiry.
The court then turned to the question
of whether there would have been
adequate motivation to combine the
prior art elements as had been urged by
Master Lock. The court recalled the
Graham inquiries, and also emphasized
the ‘‘expansive and flexible’’ post-KSR
approach to obviousness that must not
‘‘deny factfinders recourse to common
sense.’’ Wyers, slip op. at 13 (quoting
KSR, 550 U.S. at 415 and 421). The
court stated:
KSR and our later cases establish that the
legal determination of obviousness may
include recourse to logic, judgment, and
common sense, in lieu of expert testimony
* * *.
Thus, in appropriate cases, the ultimate
inference as to the existence of a motivation
to combine references may boil down to a
question of ‘‘common sense,’’ appropriate for
resolution on summary judgment or JMOL.
Id. at 15 (citing Perfect Web Techs., Inc.
v. InfoUSA, Inc., 587 F.3d 1324, 1329
(Fed. Cir. 2009); Ball Aerosol, 555 F.3d
at 993).
After reviewing these principles, the
court proceeded to explain why
adequate motivation to combine had
been established in this case. With
regard to the sleeve improvement, it
pointed out that the need for different
sizes of hitch pins was well known in
the art, and that this was a known
source of inconvenience and expense
for users. The court also mentioned the
marketplace aspect of the issue, noting
that space on store shelves was at a
premium, and that removable sleeves
addressed this economic concern. As to
the sealing improvement, the court
pointed out that both internal and
external seals were well-known means
to protect locks from contaminants. The
court concluded that the constituent
elements were being employed in
accordance with their recognized
functions, and would have predictably
retained their respective functions when
combined as suggested by Master Lock.
The court cited In re O’Farrell, 853 F.2d
894, 904 (Fed. Cir. 1988) for the
proposition that a reasonable
expectation of success is a requirement
for a proper determination of
obviousness.
Office personnel should note that
although the Federal Circuit invoked the
idea of common sense in support of a
conclusion of obviousness, it did not
end its explanation there. Rather, the
E:\FR\FM\01SEN1.SGM
01SEN1
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
court explained why a person of
ordinary skill in the art at the time of
the invention, in view of the facts
relevant to the case, would have found
the claimed inventions to have been
obvious. As stated in the MPEP:
hsrobinson on DSK69SOYB1PROD with NOTICES
The key to supporting any rejection under
35 U.S.C. 103 is the clear articulation of the
reason(s) why the claimed invention would
have been obvious. The Supreme Court in
KSR noted that the analysis supporting a
rejection under 35 U.S.C. 103 should be
made explicit. The Court quoting In re Kahn,
441 F.3d 977, 988, 78 USPQ2d 1329, 1336
(Fed. Cir. 2006), stated that ‘‘[R]ejections on
obviousness cannot be sustained by mere
conclusory statements; instead, there must be
some articulated reasoning with some
rational underpinning to support the legal
conclusion of obviousness.’’
MPEP § 2141 III. Office personnel
should continue to provide a reasoned
explanation for every obviousness
rejection.
Example 4.6. DePuy Spine, Inc. v.
Medtronic Sofamor Danek, Inc., 567
F.3d 1314 (Fed. Cir. 2009). Teaching
point: Predictability as discussed in KSR
encompasses the expectation that prior
art elements are capable of being
combined, as well as the expectation
that the combination would have
worked for its intended purpose. An
inference that a claimed combination
would not have been obvious is
especially strong where the prior art’s
teachings undermine the very reason
being proffered as to why a person of
ordinary skill would have combined the
known elements.
The claim in DePuy Spine was
directed to a polyaxial pedicle screw
used in spinal surgeries that included a
compression member for pressing a
screw head against a receiver member.
A prior art reference (Puno) disclosed
all of the elements of the claim except
for the compression member. Instead,
the screw head in Puno was separated
from the receiver member to achieve a
shock absorber effect, allowing some
motion between receiver member and
the vertebrae. The missing compression
member was readily found in another
prior art reference (Anderson), which
disclosed an external fracture
immobilization splint for immobilizing
long bones with a swivel clamp capable
of polyaxial movement until rigidly
secured by a compression member. It
was asserted during trial that a person
of ordinary skill would have recognized
that the addition of Anderson’s
compression member to Puno’s device
would have achieved a rigidly locked
polyaxial pedicle screw covered by the
claim.
In conducting its analysis, the Federal
Circuit noted that the ‘‘predictable
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
result’’ discussed in KSR refers not only
to the expectation that prior art
elements are capable of being physically
combined, but also that the combination
would have worked for its intended
purpose. In this case, it was successfully
argued that Puno ‘‘teaches away’’ from a
rigid screw because Puno warned that
rigidity increases the likelihood that the
screw will fail within the human body,
rendering the device inoperative for its
intended purpose. In fact, the reference
did not merely express a general
preference for pedicle screws having a
‘‘shock absorber’’ effect, but rather
expressed concern for failure and stated
that the shock absorber feature
‘‘decrease[s] the chance of failure of the
screw of the bone-screw interface’’
because ‘‘it prevent[s] direct transfer of
load from the rod to the bone-screw
interface.’’ Thus, the alleged reason to
combine the prior art elements of Puno
and Anderson—increasing the rigidity
of the screw—ran contrary to the prior
art that taught that increasing rigidity
would result in a greater likelihood of
failure. In view of this teaching and the
backdrop of collective teachings of the
prior art, the Federal Circuit determined
that Puno teaches away from the
proposed combination such that a
person of ordinary skill would have
been deterred from combining the
references as proposed. Secondary
considerations evaluated by the Federal
Circuit relating to failure by others and
copying also supported the view that
the combination would not have been
obvious at the time of the invention.
B. Substituting One Known Element
for Another. As explained in the 2007
KSR Guidelines, the substitution
rationale applies when the claimed
invention can be viewed as resulting
from substituting a known element for
an element of a prior art invention. The
rationale applies when one of ordinary
skill in the art would have been
technologically capable of making the
substitution, and the result obtained
would have been predictable. See MPEP
§ 2143(B).
Example 4.7. In re ICON Health &
Fitness, Inc., 496 F.3d 1374 (Fed. Cir.
2007). Teaching point: When
determining whether a reference in a
different field of endeavor may be used
to support a case of obviousness (i.e., is
analogous), it is necessary to consider
the problem to be solved.
The claimed invention in ICON was
directed to a treadmill with a folding
tread base that swivels into an upright
storage position, including a gas spring
connected between the tread base and
the upright structure to assist in stably
retaining the tread base in the storage
position. On reexamination, the
PO 00000
Frm 00020
Fmt 4703
Sfmt 4703
53649
examiner rejected the claims as obvious
based on a combination of references
including an advertisement (Damark) for
a folding treadmill demonstrating all of
the claim elements other than the gas
spring, and a patent (Teague) with a gas
spring. Teague was directed to a bed
that folds into a cabinet using a novel
dual-action spring that reverses force as
the mechanism passes a neutral
position, rather than a single-action
spring that would provide a force
pushing the bed closed at all times. The
dual-action spring reduced the force
required to open the bed from the closed
position, while reducing the force
required to lift the bed from the open
position.
The Federal Circuit addressed the
propriety of making the combination
since Teague comes from a different
field than the application. Teague was
found to be reasonably pertinent to the
problem addressed in the application
because the folding mechanism did not
require any particular focus on
treadmills, but rather generally
addressed problems of supporting the
weight of such a mechanism and
providing a stable resting position.
Other evidence was considered
concerning whether one skilled in the
art would have been led to combine the
teachings of Damark and Teague.
Appellant argued that Teague teaches
away from the invention because it
directs one skilled in the art not to use
single-action springs and does not
satisfy the claim limitations as the dualaction springs would render the
invention inoperable. The Federal
Circuit considered the arguments and
found that while Teague at most teaches
away from using single-action springs to
decrease the opening force, it actually
instructed that single-action springs
provide the result desired by the
inventors, which was to increase the
opening force provided by gravity. As to
inoperability, the claims were not
limited to single-action springs and
were so broad as to encompass anything
that assists in stably retaining the tread
base, which is the function that Teague
accomplished. Additionally, the fact
that the counterweight mechanism from
Teague used a large spring, which
appellant argued would overpower the
treadmill mechanism, ignores the
modifications that one skilled in the art
would make to a device borrowed from
the prior art. One skilled in the art
would size the components from Teague
appropriately for the application.
ICON is another useful example for
understanding the scope of analogous
art. The art applied concerned retaining
mechanisms for folding beds, not
treadmills. When determining whether a
E:\FR\FM\01SEN1.SGM
01SEN1
hsrobinson on DSK69SOYB1PROD with NOTICES
53650
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
reference may properly be applied to an
invention in a different field of
endeavor, it is necessary to consider the
problem to be solved. It is certainly
possible that a reference may be drawn
in such a way that its usefulness as a
teaching is narrowly restricted.
However, in ICON, the ‘‘treadmill’’
concept was too narrow a lens through
which to view the art in light of the
prior art teachings concerning the
problem to be solved. The Teague
reference was analogous art because
‘‘Teague and the current application
both address the need to stably retain a
folding mechanism,’’ id. at 1378, and
because ‘‘nothing about ICON’s folding
mechanism requires any particular
focus on treadmills,’’ id. at 1380.
ICON is also informative as to the
relationship between the problem to be
solved and existence of a reason to
combine. ‘‘Indeed, while perhaps not
dispositive of the issue, the finding that
Teague, by addressing a similar
problem, provides analogous art to
ICON’s application goes a long way
towards demonstrating a reason to
combine the two references. Because
ICON’s broad claims read on
embodiments addressing that problem
as described by Teague, the prior art
here indicates a reason to incorporate its
teachings.’’ Id. at 1380–81.
The Federal Circuit’s discussion in
ICON also makes clear that if the
reference does not teach that a
combination is undesirable, then it
cannot be said to teach away. An
assessment of whether a combination
would render the device inoperable
must not ‘‘ignore the modifications that
one skilled in the art would make to a
device borrowed from the prior art.’’ Id.
at 1382.
Example 4.8. Agrizap, Inc. v.
Woodstream Corp., 520 F.3d 1337 (Fed.
Cir. 2008). Teaching point: Analogous
art is not limited to references in the
field of endeavor of the invention, but
also includes references that would
have been recognized by those of
ordinary skill in the art as useful for
applicant’s purpose.
Agrizap involved a stationary pest
control device for electrocution of pests
such as rats and gophers, in which the
device is set in an area where the pest
is likely to encounter it. The only
difference between the claimed device
and the prior art stationary pest control
device was that the claimed device
employed a resistive electrical switch,
while the prior art device used a
mechanical pressure switch. A resistive
electrical switch was taught in two prior
art patents, in the contexts of a handheld pest control device and a cattle
prod.
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
In determining that the claimed
invention was obvious, the Federal
Circuit noted that ‘‘[t]he asserted claims
simply substitute a resistive electrical
switch for the mechanical pressure
switch’’ employed in the prior art
device. Id. at 1344. In this case, the prior
art concerning the hand-held devices
revealed that the function of the
substituted resistive electrical switch
was well known and predictable, and
that it could be used in a pest control
device. According to the Federal Circuit,
the references that taught the hand-held
devices showed that ‘‘the use of an
animal body as a resistive switch to
complete a circuit for the generation of
an electric charge was already well
known in the prior art.’’ Id. Finally, the
Federal Circuit noted that the problem
solved by using the resistive electrical
switch in the prior art hand-held
devices—malfunction of mechanical
switches due to dirt and dampness—
also pertained to the prior art stationary
pest control device.
The Federal Circuit recognized
Agrizap as ‘‘a textbook case of when the
asserted claims involve a combination
of familiar elements according to known
methods that does no more than yield
predictable results.’’ Id. Agrizap
exemplifies a strong case of obviousness
based on simple substitution that was
not overcome by the objective evidence
of nonobviousness offered. It also
demonstrates that analogous art is not
limited to the field of applicant’s
endeavor, in that one of the references
that used an animal body as a resistive
switch to complete a circuit for the
generation of an electric charge was not
in the field of pest control.
Example 4.9. Muniauction, Inc. v.
Thomson Corp., 532 F.3d 1318 (Fed.
Cir. 2008). Teaching point: Because
Internet and Web browser technologies
had become commonplace for
communicating and displaying
information, it would have been obvious
to adapt existing processes to
incorporate them for those functions.
The invention at issue in Muniauction
was a method for auctioning municipal
bonds over the Internet. A municipality
could offer a package of bond
instruments of varying principal
amounts and maturity dates, and an
interested buyer would then submit a
bid comprising a price and interest rate
for each maturity date. It was also
possible for the interested buyer to bid
on a portion of the offering. The claimed
invention considered all of the noted
parameters to determine the best bid. It
operated on conventional Web browsers
and allowed participants to monitor the
course of the auction.
PO 00000
Frm 00021
Fmt 4703
Sfmt 4703
The only difference between the prior
art bidding system and the claimed
invention was the use of a conventional
Web browser. At trial, the district court
had determined that Muniauction’s
claims were not obvious. Thomson
argued that the claimed invention
amounted to incorporating a Web
browser into a prior art auction system,
and was therefore obvious in light of
KSR. Muniauction rebutted the
argument by offering evidence of
skepticism by experts, copying, praise,
and commercial success. Although the
district court found the evidence to be
persuasive of nonobviousness, the
Federal Circuit disagreed. It noted that
a nexus between the claimed invention
and the proffered evidence was lacking
because the evidence was not
coextensive with the claims at issue. For
this reason, the Federal Circuit
determined that Muniauction’s evidence
of secondary considerations was not
entitled to substantial weight.
The Federal Circuit analogized this
case to Leapfrog Enterprises, Inc. v.
Fisher-Price, Inc., 485 F.3d 1157 (Fed.
Cir. 2007), cited in the 2007 KSR
Guidelines. The Leapfrog case involved
a determination of obviousness based on
application of modern electronics to a
prior art mechanical children’s learning
device. In Leapfrog, the court had noted
that market pressures would have
prompted a person of ordinary skill to
use modern electronics in the prior art
device. Similarly in Muniauction,
market pressures would have prompted
a person of ordinary skill to use a
conventional Web browser in a method
of auctioning municipal bonds.
Example 4.10. Aventis Pharma
Deutschland v. Lupin Ltd., 499 F.3d
1293 (Fed. Cir. 2007). Teaching point: A
chemical compound would have been
obvious over a mixture containing that
compound as well as other compounds
where it was known or the skilled
artisan had reason to believe that some
desirable property of the mixture was
derived in whole or in part from the
claimed compound, and separating the
claimed compound from the mixture
was routine in the art.
In Aventis, the claims were drawn to
the 5(S) stereoisomer of the blood
pressure drug ramipril in
stereochemically pure form, and to
compositions and methods requiring
5(S) ramipril. The 5(S) stereoisomer is
one in which all five stereocenters in
the ramipril molecule are in the S rather
than the R configuration. A mixture of
various stereoisomers including 5(S)
ramipril had been taught by the prior
art. The question before the court was
whether the purified single stereoisomer
E:\FR\FM\01SEN1.SGM
01SEN1
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
would have been obvious over the
known mixture of stereoisomers.
The record showed that the presence
of multiple S stereocenters in drugs
similar to ramipril was known to be
associated with enhanced therapeutic
efficacy. For example, when all of the
stereocenters were in the S form in the
related drug enalapril (SSS enalapril) as
compared with only two stereocenters
in the S form (SSR enalapril), the
therapeutic potency was 700 times as
great. There was also evidence to
indicate that conventional methods
could be used to separate the various
stereoisomers of ramipril.
The district court saw the issue as a
close case, because, in its view, there
was no clear motivation in the prior art
to isolate 5(S) ramipril. However, the
Federal Circuit disagreed, and found
that the claims would have been
obvious. The Federal Circuit cautioned
that requiring such a clearly stated
motivation in the prior art to isolate 5(S)
ramipril ran counter to the Supreme
Court’s decision in KSR. The court
stated:
hsrobinson on DSK69SOYB1PROD with NOTICES
Requiring an explicit teaching to purify the
5(S) stereoisomer from a mixture in which it
is the active ingredient is precisely the sort
of rigid application of the TSM test that was
criticized in KSR.
Id. at 1301. The Aventis court also
relied on the settled principle that in
chemical cases, structural similarity can
provide the necessary reason to modify
prior art teachings. The Federal Circuit
also addressed the kind of teaching that
would be sufficient in the absence of an
explicitly stated prior art-based
motivation, explaining that an
expectation of similar properties in light
of the prior art can be sufficient, even
without an explicit teaching that the
compound will have a particular utility.
In the chemical arts, the cases
involving so-called ‘‘lead compounds’’
form an important subgroup of the
obviousness cases that are based on
substitution. The Federal Circuit has
had a number of opportunities since the
KSR decision to discuss the
circumstances under which it would
have been obvious to modify a known
compound to arrive at a claimed
compound. The following cases explore
the selection of a lead compound, the
need to provide a reason for any
proposed modification, and the
predictability of the result.
Example 4.11. Eisai Co. Ltd. v. Dr.
Reddy’s Labs., Ltd., 533 F.3d 1353 (Fed.
Cir. 2008). Teaching point: A claimed
compound would not have been
obvious where there was no reason to
modify the closest prior art lead
compound to obtain the claimed
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
compound and the prior art taught that
modifying the lead compound would
destroy its advantageous property. Any
known compound may serve as a lead
compound when there is some reason
for starting with that lead compound
and modifying it to obtain the claimed
compound.
Eisai concerns the pharmaceutical
compound rabeprazole. Rabeprazole is a
proton pump inhibitor for treating
stomach ulcers and related disorders.
The Federal Circuit affirmed the district
court’s summary judgment of
nonobviousness, stating that no reason
had been advanced to modify the prior
art compound in a way that would
destroy an advantageous property.
Co-defendant Teva based its
obviousness argument on the structural
similarity between rabeprazole and
lansoprazole. The compounds were
recognized as sharing a common core,
and the Federal Circuit characterized
lansoprazole as a ‘‘lead compound.’’ The
prior art compound lansoprazole was
useful for the same indications as
rabeprazole, and differed from
rabeprazole only in that lansoprazole
has a trifluoroethoxy substituent at the
4-position of the pyridine ring, while
rabeprazole has a methoxypropoxy
substituent. The trifluoro substituent of
lansoprazole was known to be a
beneficial feature because it conferred
lipophilicity to the compound. The
ability of a person of ordinary skill to
carry out the modification to introduce
the methoxypropoxy substituent, and
the predictability of the result were not
addressed.
Despite the significant similarity
between the structures, the Federal
Circuit did not find any sufficient
reason to modify the lead compound.
According to the Federal Circuit:
Obviousness based on structural similarity
thus can be proved by identification of some
motivation that would have led one of
ordinary skill in the art to select and then
modify a known compound (i.e. a lead
compound) in a particular way to achieve the
claimed compound. * * * In keeping with
the flexible nature of the obviousness
inquiry, KSR Int’l Co. v. Teleflex Inc., 550
U.S. 398, 127 S.Ct. 1727, 1739, 167 L.Ed.2d
705 (2007), the requisite motivation can come
from any number of sources and need not
necessarily be explicit in the art. See Aventis
Pharma Deutschland GmbH v. Lupin, Ltd.,
499 F.3d 1293, 1301 (Fed. Cir. 2007). Rather
‘‘it is sufficient to show that the claimed and
prior art compounds possess a ‘sufficiently
close relationship * * * to create an
expectation,’ in light of the totality of the
prior art, that the new compound will have
‘similar properties’ to the old.’’ Id. (quoting
Dillon, 919 F.2d at 692).
Eisai, 533 F.3d at 1357. The prior art
taught that introducing a fluorinated
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
53651
substituent was known to increase
lipophilicity, so a skilled artisan would
have expected that replacing the
trifluoroethoxy substituent with a
methoxypropoxy substituent would
have reduced the lipophilicity of the
compound. Thus, the prior art created
the expectation that rabeprazole would
be less useful than lansoprazole as a
drug for treating stomach ulcers and
related disorders because the proposed
modification would have destroyed an
advantageous property of the prior art
compound. The compound was not
obvious as argued by Teva because,
upon consideration of all of the facts of
the case, a person of ordinary skill in
the art at the time of the invention
would not have had a reason to modify
lansoprazole so as to form rabeprazole.
Office personnel are cautioned that
the term ‘‘lead compound’’ in a
particular opinion can have a contextual
meaning that may vary from the way a
pharmaceutical chemist might use the
term. In the field of pharmaceutical
chemistry, the term ‘‘lead compound’’
has been defined variously as ‘‘a
chemical compound that has
pharmacological or biological activity
and whose chemical structure is used as
a starting point for chemical
modifications in order to improve
potency, selectivity, or pharmacokinetic
parameters;’’ ‘‘[a] compound that
exhibits pharmacological properties
which suggest its development;’’ and ‘‘a
potential drug being tested for safety
and efficacy.’’ See, e.g.,https://
en.wikipedia.org/wiki/Lead_compound,
accessed January 13, 2010; https://
www.combichemistry.com/
glossary_k.html, accessed January 13,
2010; and https://www.building
biotechnology.com/glossary4.php,
accessed January 13, 2010.
The Federal Circuit in Eisai makes it
clear that from the perspective of the
law of obviousness, any known
compound might possibly serve as a
lead compound: ‘‘Obviousness based on
structural similarity thus can be proved
by identification of some motivation
that would have led one of ordinary
skill in the art to select and then modify
a known compound (i.e. a lead
compound) in a particular way to
achieve the claimed compound.’’ Eisai,
533 F.3d at 1357. Thus, Office personnel
should recognize that a proper
obviousness rejection of a claimed
compound that is useful as a drug might
be made beginning with an inactive
compound, if, for example, the reasons
for modifying a prior art compound to
arrive at the claimed compound have
nothing to do with pharmaceutical
activity. The inactive compound would
not be considered to be a lead
E:\FR\FM\01SEN1.SGM
01SEN1
hsrobinson on DSK69SOYB1PROD with NOTICES
53652
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
compound by pharmaceutical chemists,
but could potentially be used as such
when considering obviousness. Office
personnel might also base an
obviousness rejection on a known
compound that pharmaceutical
chemists would not select as a lead
compound due to expense, handling
issues, or other business considerations.
However, there must be some reason for
starting with that lead compound other
than the mere fact that the ‘‘lead
compound’’ merely exists. See Altana
Pharma AG v. Teva Pharmaceuticals
USA, Inc., 566 F.3d 999, 1007 (Fed. Cir.
2009) (holding that there must be some
reason ‘‘to select and modify a known
compound’’); Ortho-McNeil
Pharmaceutical, Inc. v. Mylan Labs,
Inc., 520 F.3d 1358, 1364 (Fed. Cir.
2008).
Example 4.12. Procter & Gamble Co.
v. Teva Pharmaceuticals USA, Inc., 566
F.3d 989 (Fed. Cir. 2009). Teaching
point: It is not necessary to select a
single compound as a ‘‘lead compound’’
in order to support an obviousness
rejection. However, where there was
reason to select and modify the lead
compound to obtain the claimed
compound, but no reasonable
expectation of success, the claimed
compound would not have been
obvious.
A chemical compound was also found
to be nonobvious in Procter & Gamble.
The compound at issue was
risedronate—the active ingredient of
Procter & Gamble’s osteoporosis drug
Actonel®. Risedronate is an example of
a bisphosphonate, which is a class of
compounds known to inhibit bone
resorption.
When Procter & Gamble sued Teva for
infringement, Teva defended by arguing
invalidity for obviousness over one of
Procter & Gamble’s earlier patents. The
prior art patent did not teach
risedronate, but instead taught thirty-six
other similar compounds including 2pyr EHDP that were potentially useful
with regard to osteoporosis. Teva argued
obviousness on the basis of structural
similarity to 2-pyr EHDP, which is a
positional isomer of risedronate.
The district court found no reason to
select 2-pyr EHDP as a lead compound
in light of the unpredictable nature of
the art, and no reason to modify it so as
to obtain risedronate. In addition, there
were unexpected results as to potency
and toxicity. Therefore the district court
found that Teva had not made a prima
facie case, and even if it had, it was
rebutted by evidence of unexpected
results.
The Federal Circuit affirmed the
district court’s decision. The Federal
Circuit did not deem it necessary in this
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
case to consider the question of whether
2-pyr EHDP had been appropriately
selected as a lead compound. Rather,
the Federal Circuit stated that if 2-pyr
EHDP is presumed to be an appropriate
lead compound, there must be both a
reason to modify it so as to make
risedronate, and a reasonable
expectation of success. Here there was
no evidence that the necessary
modifications would have been routine,
so there would have been no reasonable
expectation of success.
Procter & Gamble is also informative
in its discussion of the treatment of
secondary considerations of nonobviousness. Although the court found
that no prima facie case of obviousness
had been presented, it proceeded to
analyze Procter & Gamble’s proffered
evidence countering the alleged prima
facie case in some detail, thus shedding
light on the proper treatment of such
evidence.
The Federal Circuit noted in dicta that
even if a prima facie case of obviousness
had been established, sufficient
evidence of unexpected results was
introduced to rebut such a showing. At
trial, the witnesses consistently testified
that the properties of risedronate were
not expected, offering evidence that
researchers did not predict either the
potency or the low dose at which the
compound was effective, and that the
superior properties were unexpected
and could not be predicted. Tests
comparing risedronate to a compound
in the prior art reference showed that
risedronate outperformed the other
compound by a substantial margin,
could be administered in a greater
amount without an observable toxic
effect, and was not lethal at the same
levels as the other compound. The
weight of the evidence and the
credibility of the witnesses were
sufficient to show unexpected results
that would have rebutted an
obviousness determination. Thus,
nonobviousness can be shown when a
claimed invention is shown to have
unexpectedly superior properties when
compared to the prior art.
The court then addressed the
evidence of commercial success of
risedronate and the evidence that
risedronate met a long-felt need. The
court pointed out that little weight was
to be afforded to the commercial success
because the competing product was also
assigned to Procter & Gamble. However,
the Federal Circuit affirmed the district
court’s conclusion that risedronate met
a long-felt, unsatisfied need. The court
rejected Teva’s contention that because
the competing drug was available before
Actonel®, there was no unmet need that
the invention satisfied. The court
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
emphasized that whether there was a
long-felt unsatisfied need is to be
evaluated based on the circumstances as
of the filing date of the challenged
invention—not as of the date that the
invention is brought to market.
It should be noted that the lead
compound cases do not stand for the
proposition that identification of a
single lead compound is necessary in
every obviousness rejection of a
chemical compound. For example, one
might envision a suggestion in the prior
art to formulate a compound having
certain structurally defined moieties, or
moieties with certain properties. If a
person of ordinary skill would have
known how to synthesize such a
compound, and the structural and/or
functional result could reasonably have
been predicted, then a prima facie case
of obviousness of the claimed chemical
compound might exist even without
identification of a particular lead
compound. As a second example, it
could be possible to view a claimed
compound as consisting of two known
compounds attached via a chemical
linker. The claimed compound might
properly be found to have been obvious
if there would have been a reason to
link the two, if one of ordinary skill
would have known how to do so, and
if the resulting compound would have
been the predictable result of the
linkage procedure. Thus, Office
personnel should recognize that in
certain situations, it may be proper to
reject a claimed chemical compound as
obvious even without identifying a
single lead compound.
Example 4.13. Altana Pharma AG v.
Teva Pharmaceuticals USA, Inc., 566
F.3d 999 (Fed. Cir. 2009). Teaching
point: Obviousness of a chemical
compound in view of its structural
similarity to a prior art compound may
be shown by identifying some line of
reasoning that would have led one of
ordinary skill in the art to select and
modify a prior art lead compound in a
particular way to produce the claimed
compound. It is not necessary for the
reasoning to be explicitly found in the
prior art of record, nor is it necessary for
the prior art to point to only a single
lead compound.
Although the decision reached by the
Federal Circuit in Altana involved a
motion for preliminary injunction and
did not include a final determination of
obviousness, the case is nevertheless
instructive as to the issue of selecting a
lead compound.
The technology involved in Altana
was the compound pantoprazole, which
is the active ingredient in Altana’s
antiulcer drug Protonix®. Pantoprazole
belongs to a class of compounds known
E:\FR\FM\01SEN1.SGM
01SEN1
hsrobinson on DSK69SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
as proton pump inhibitors that are used
to treat gastric acid disorders in the
stomach.
Altana accused Teva of infringement.
The district court denied Altana’s
motion for preliminary injunction for
failure to establish a likelihood of
success on the merits, determining that
Teva had demonstrated a substantial
question of invalidity for obviousness in
light of one of Altana’s prior patents.
Altana’s patent discussed a compound
referred to as compound 12, which was
one of eighteen compounds disclosed.
The claimed compound pantoprazole
was structurally similar to compound
12. The district court found that one of
ordinary skill in the art would have
selected compound 12 as a lead
compound for modification, and the
Federal Circuit affirmed.
Obviousness of a chemical compound
in view of its structural similarity to a
prior art compound may be shown by
identifying some line of reasoning that
would have led one of ordinary skill in
the art to select and modify the prior art
compound in a particular way to
produce the claimed compound. The
necessary line of reasoning can be
drawn from any number of sources and
need not necessarily be explicitly found
in the prior art of record. The Federal
Circuit determined that ample evidence
supported the district court’s finding
that compound 12 was a natural choice
for further development. For example,
Altana’s prior art patent claimed that its
compounds, including compound 12,
were improvements over the prior art;
compound 12 was disclosed as one of
the more potent of the eighteen
compounds disclosed; the patent
examiner had considered the
compounds of Altana’s prior art patent
to be relevant during the prosecution of
the patent in suit; and experts had
opined that one of ordinary skill in the
art would have selected the eighteen
compounds to pursue further
investigation into their potential as
proton pump inhibitors.
In response to Altana’s argument that
the prior art must point to only a single
lead compound for further
development, the Federal Circuit stated
that a ‘‘restrictive view of the lead
compound test would present a rigid
test similar to the teaching-suggestionmotivation test that the Supreme Court
explicitly rejected in KSR * * *. The
district court in this case employed a
flexible approach—one that was
admittedly preliminary—and found that
the defendants had raised a substantial
question that one of skill in the art
would have used the more potent
compounds of [Altana’s prior art]
patent, including compound 12, as a
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
starting point from which to pursue
further development efforts. That
finding was not clearly erroneous.’’ Id. at
1008.
C. The ‘‘Obvious to Try’’ Rationale.
The question of whether a claimed
invention can be shown to be obvious
based on an ‘‘obvious to try’’ line of
reasoning has been explored extensively
by the Federal Circuit in several cases
since the KSR decision. The 2007 KSR
Guidelines explain, in view of the
Supreme Court’s instruction, that this
rationale is only appropriate when there
is a recognized problem or need in the
art; there are a finite number of
identified, predictable solutions to the
recognized need or problem; and one of
ordinary skill in the art could have
pursued these known potential
solutions with a reasonable expectation
of success. The case law in this area is
developing quickly in the chemical arts,
although the rationale has been applied
in other art areas as well.
Some commentators on the KSR
decision have expressed a concern that
because inventive activities are always
carried out in the context of what has
come before and not in a vacuum, few
inventions will survive scrutiny under
an obvious to try standard. The cases
decided since KSR have proved this fear
to have been unfounded. Courts appear
to be applying the KSR requirement for
‘‘a finite number of identified
predictable solutions’’ in a manner that
places particular emphasis on
predictability and the reasonable
expectations of those of ordinary skill in
the art.
In a recent Federal Circuit decision,
the court pointed out the challenging
nature of the task faced by the courts—
and likewise by Office personnel—when
considering the viability of an obvious
to try argument: ‘‘The evaluation of the
choices made by a skilled scientist,
when such choices lead to the desired
result, is a challenge to judicial
understanding of how technical advance
is achieved in the particular field of
science or technology.’’ Abbott Labs. v.
Sandoz, Inc., 544 F.3d 1341, 1352 (Fed.
Cir. 2008). The Federal Circuit
cautioned that an obviousness inquiry
based on an obvious to try rationale
must always be undertaken in the
context of the subject matter in
question, ‘‘including the characteristics
of the science or technology, its state of
advance, the nature of the known
choices, the specificity or generality of
the prior art, and the predictability of
results in the area of interest.’’ Id.
Example 4.14. In re Kubin, 561 F.3d
1351 (Fed. Cir. 2009). Teaching point: A
claimed polynucleotide would have
been obvious over the known protein
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
53653
that it encodes where the skilled artisan
would have had a reasonable
expectation of success in deriving the
claimed polynucleotide using standard
biochemical techniques, and the skilled
artisan would have had a reason to try
to isolate the claimed polynucleotide.
KSR applies to all technologies, rather
than just the ‘‘predictable’’ arts.
The Federal Circuit’s decision in In re
Kubin was an affirmance of the Board’s
decision in Ex parte Kubin, 83 USPQ2d
1410 (Bd. Pat. App. & Interf. 2007), and
the Board in turn had affirmed the
examiner’s determination that the
claims in question would have been
obvious over the prior art applied. A
discussion of Ex parte Kubin was
included in the 2007 KSR Guidelines.
See 2007 KSR Guidelines, 72 FR at
57532. The claimed invention in Kubin
was an isolated nucleic acid molecule.
The claim stated that the nucleic acid
encoded a particular polypeptide. The
encoded polypeptide was identified in
the claim by its partially specified
sequence, and by its ability to bind to
a specified protein. A prior art patent to
Valiante taught the polypeptide
encoded by the claimed nucleic acid,
but did not disclose either the sequence
of the polypeptide, or the claimed
isolated nucleic acid molecule.
However, Valiante did disclose that by
employing conventional methods, such
as those disclosed by a prior art
laboratory manual by Sambrook, the
sequence of the polypeptide could be
determined, and the nucleic acid
molecule could be isolated. In view of
Valiante’s disclosure of the polypeptide,
and of routine prior art methods for
sequencing the polypeptide and
isolating the nucleic acid molecule, the
Board found that a person of ordinary
skill in the art would have had a
reasonable expectation that a nucleic
acid molecule within the claimed scope
could have been successfully obtained.
Relying on In re Deuel, 51 F.3d 1552
(Fed. Cir. 1995), Appellant argued that
it was improper for the Office to use the
polypeptide of the Valiante patent
together with the methods described in
Sambrook to reject a claim drawn to a
specific nucleic acid molecule without
providing a reference showing or
suggesting a structurally similar nucleic
acid molecule. Citing KSR, the Board
stated that ‘‘when there is motivation to
solve a problem and there are a finite
number of identified, predictable
solutions, a person of ordinary skill has
good reason to pursue the known
options within his or her technical
grasp. If this leads to anticipated
success, it is likely the product not of
innovation but of ordinary skill and
common sense.’’ The Board noted that
E:\FR\FM\01SEN1.SGM
01SEN1
hsrobinson on DSK69SOYB1PROD with NOTICES
53654
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
the problem facing those in the art was
to isolate a specific nucleic acid, and
there were a limited number of methods
available to do so. The Board concluded
that the skilled artisan would have had
reason to try these methods with the
reasonable expectation that at least one
would be successful. Thus, isolating the
specific nucleic acid molecule claimed
was ‘‘the product not of innovation but
of ordinary skill and common sense.’’
The Board’s reasoning was substantially
adopted by the Federal Circuit.
However, it is important to note that in
the Kubin decision, the Federal Circuit
held that ‘‘the Supreme Court in KSR
unambiguously discredited’’ the Federal
Circuit’s decision in Deuel, insofar as it
‘‘implies the obviousness inquiry cannot
consider that the combination of the
claim’s constituent elements was
‘obvious to try.’ ’’ Kubin, 561 F.3d at
1358. Instead, Kubin stated that KSR
‘‘resurrects’’ the Federal Circuit’s own
wisdom in O’Farrell, in which ‘‘to
differentiate between proper and
improper applications of ‘obvious to
try,’ ’’ the Federal Circuit ‘‘outlined two
classes of situations where ‘obvious to
try’ is erroneously equated with
obviousness under § 103.’’ Kubin, 561
F.3d at 1359. These two classes of
situations are: (1) When what would
have been ‘‘obvious to try’’ would have
been to vary all parameters or try each
of numerous possible choices until one
possibly arrived at a successful result,
where the prior art gave either no
indication of which parameters were
critical or no direction as to which of
many possible choices is likely to be
successful; and (2) when what was
‘‘obvious to try’’ was to explore a new
technology or general approach that
seemed to be a promising field of
experimentation, where the prior art
gave only general guidance as to the
particular form of the claimed invention
or how to achieve it. Id. (citing
O’Farrell, 853 F.2d at 903).
Example 4.15. Takeda Chemical
Industries, Ltd. v. Alphapharm Pty.,
Ltd., 492 F.3d 1350 (Fed. Cir. 2007).
Teaching point: A claimed compound
would not have been obvious where it
was not obvious to try to obtain it from
a broad range of compounds, any one of
which could have been selected as the
lead compound for further investigation,
and the prior art taught away from using
a particular lead compound, and there
was no predictability or reasonable
expectation of success in making the
particular modifications necessary to
transform the lead compound into the
claimed compound.
Takeda is an example of a chemical
case in which the Federal Circuit found
that the claim was not obvious. The
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
claimed compound was pioglitazone, a
member of a class of drugs known as
thiazolidinediones (TZDs) marketed by
Takeda as a treatment for Type 2
diabetes. The Takeda case brings
together the concept of a ‘‘lead
compound’’ and the obvious-to-try
argument.
Alphapharm had filed an Abbreviated
New Drug Application with the Food
and Drug Administration, which was a
technical act of infringement of
Takeda’s patent. When Takeda brought
suit, Alphapharm’s defense was that
Takeda’s patent was invalid due to
obviousness. Alphapharm argued that a
two-step modification—involving
homologation and ring-walking—of a
known compound identified as
‘‘compound b’’ would have produced
pioglitazone, and that it was therefore
obvious.
The district court found that there
would have been no reason to select
compound b as a lead compound. There
were a large number of similar prior art
TZD compounds; fifty-four were
specifically identified in Takeda’s prior
patent, and the district court observed
that ‘‘hundreds of millions’’ were more
generally disclosed. Although the
parties agreed that compound b
represented the closest prior art, one
reference had taught certain
disadvantageous properties associated
with compound b, which according to
the district court would have taught the
skilled artisan not to select that
compound as a lead compound. The
district court found no prima facie case
of obviousness, and stated that even if
a prima facie case had been established,
it would have been overcome in this
case in view of the unexpected lack of
toxicity of pioglitazone.
The Federal Circuit affirmed the
decision of the district court, citing the
need for a reason to modify a prior art
compound. The Federal Circuit quoted
KSR, stating:
The KSR Court recognized that ‘‘[w]hen
there is a design need or market pressure to
solve a problem and there are a finite number
of identified, predictable solutions, a person
of ordinary skill has good reason to pursue
the known options within his or her
technical grasp.’’ KSR, 127 S.Ct. at 1732. In
such circumstances, ‘‘the fact that a
combination was obvious to try might show
that it was obvious under § 103.’’ Id. That is
not the case here. Rather than identify
predictable solutions for antidiabetic
treatment, the prior art disclosed a broad
selection of compounds any one of which
could have been selected as a lead compound
for further investigation. Significantly, the
closest prior art compound (compound b, the
6-methyl) exhibited negative properties that
would have directed one of ordinary skill in
the art away from that compound. Thus, this
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
case fails to present the type of situation
contemplated by the Court when it stated
that an invention may be deemed obvious if
it was ‘‘obvious to try.’’ The evidence showed
that it was not obvious to try.
Takeda, 492 F.3d at 1359.
Accordingly, Office personnel should
recognize that the obvious to try
rationale does not apply when the
appropriate factual findings cannot be
made. In Takeda, there was a
recognized need for treatment of
diabetes. However, there was no finite
number of identified, predictable
solutions to the recognized need, and no
reasonable expectation of success. There
were numerous known TZD
compounds, and although one clearly
represented the closest prior art, its
known disadvantages rendered it
unsuitable as a starting point for further
research, and taught the skilled artisan
away from its use. Furthermore, even if
there had been reason to select
compound b, there had been no
predictability or reasonable expectation
of success associated with the particular
modifications necessary to transform
compound b into the claimed
compound pioglitazone. Thus, an
obviousness rejection based on an
obvious to try rationale was not
appropriate in this situation.
Example 4.16. Ortho-McNeil
Pharmaceutical, Inc. v. Mylan Labs,
Inc., 520 F.3d 1358 (Fed. Cir. 2008).
Teaching point: Where the claimed anticonvulsant drug had been discovered
somewhat serendipitously in the course
of research aimed at finding a new antidiabetic drug, it would not have been
obvious to try to obtain a claimed
compound where the prior art did not
present a finite and easily traversed
number of potential starting
compounds, and there was no apparent
reason for selecting a particular starting
compound from among a number of
unpredictable alternatives.
The Ortho-McNeil case provides
another example in which a chemical
compound was determined not to be
obvious. The claimed subject matter was
topiramate, which is used as an anticonvulsant. As in DePuy Spine, whether
the combination would predictably be
effective for its intended purpose is part
of the obviousness analysis.
In the course of working toward a new
anti-diabetic drug, Ortho-McNeil’s
scientist had unexpectedly discovered
that a reaction intermediate had anticonvulsant properties. Mylan’s defense
of invalidity due to obviousness rested
on an obvious to try argument.
However, Mylan did not explain why it
would have been obvious to begin with
an anti-diabetic drug precursor,
especially the specific one that led to
E:\FR\FM\01SEN1.SGM
01SEN1
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
topiramate, if one had been seeking an
anti-convulsant drug. The district court
ruled on summary judgment that OrthoMcNeil’s patent was not invalid for
obviousness.
The Federal Circuit affirmed. The
Federal Circuit pointed out that there
was no apparent reason why a person of
ordinary skill would have chosen the
particular starting compound or the
particular synthetic pathway that led to
topiramate as an intermediate.
Furthermore, there would have been no
reason to test that intermediate for
anticonvulsant properties if treating
diabetes had been the goal. The Federal
Circuit recognized an element of
serendipity in this case, which runs
counter to the requirement for
predictability. Summarizing their
conclusion with regard to Mylan’s
obvious to try argument, the Federal
Circuit stated:
hsrobinson on DSK69SOYB1PROD with NOTICES
[T]his invention, contrary to Mylan’s
characterization, does not present a finite
(and small in the context of the art) number
of options easily traversed to show
obviousness * * *. KSR posits a situation
with a finite, and in the context of the art,
small or easily traversed, number of options
that would convince an ordinarily skilled
artisan of obviousness* * * . [T]his clearly is
not the easily traversed, small and finite
number of alternatives that KSR suggested
might support an inference of obviousness.
Id. at 1364. Thus, Ortho-McNeil helps
to clarify the Supreme Court’s
requirement in KSR for ‘‘a finite
number’’ of predictable solutions when
an obvious to try rationale is applied:
Under the Federal Circuit’s case law
‘‘finite’’ means ‘‘small or easily
traversed’’ in the context of the art in
question. As taught in Abbott, discussed
above, it is essential that the inquiry be
placed in the context of the subject
matter at issue, and each case must be
decided on its own facts.
Example 4.17. Bayer Schering Pharma
A.G. v. Barr Labs., Inc., 575 F.3d 1341
(Fed. Cir. 2009). Teaching point: A
claimed compound would have been
obvious where it was obvious to try to
obtain it from a finite and easily
traversed number of options that was
narrowed down from a larger set of
possibilities by the prior art, and the
outcome of obtaining the claimed
compound was reasonably predictable.
In Bayer the claimed invention was an
oral contraceptive containing
micronized drospirenone marketed as
Yasmin®.
The prior art compound drospirenone
was known to be a poorly water-soluble,
acid-sensitive compound with
contraceptive effects. It was also known
in the art that micronization improves
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
the solubility of poorly water soluble
drugs.
Based on the known acid sensitivity,
Bayer had studied how effectively an
enteric-coated drospirenone tablet
delivered a formulation as compared to
an intravenous injection of the same
formulation to measure the ‘‘absolute
bioavailability’’ of the drug. Bayer added
an unprotected (normal) drospirenone
tablet and compared its bioavailability
to that of the enteric-coated formulation
and the intravenous delivery. Bayer
expected to find that the enteric-coated
tablet would produce a lower
bioavailability than an intravenous
injection, while the normal pill would
produce an even lower bioavailability
than the enteric-coated tablet. However,
they found that despite observations
that drospirenone would quickly
isomerize in a highly acidic
environment (supporting the belief that
an enteric coating would be necessary to
preserve bioavailability), the normal pill
and the enteric-coated pill resulted in
the same bioavailability. Following this
study, Bayer developed micronized
drospirenone in a normal pill, the basis
for the disputed patent.
The district court found that a person
having ordinary skill in the art would
have considered the prior art result that
a structurally related compound,
spirorenone, though acid-sensitive,
would nevertheless absorb in vivo,
would have suggested the same result
for drospirenone. It also found that
while another reference taught that
drospirenone isomerizes in vitro when
exposed to acid simulating the human
stomach, a person of ordinary skill
would have been aware of the study’s
shortcomings, and would have verified
the findings as suggested by a treatise on
the science of dosage form design,
which would have then showed that no
enteric coating was necessary.
The Federal Circuit held that the
patent was invalid because the claimed
formulation was obvious. The Federal
Circuit reasoned that the prior art would
have funneled the formulator toward
two options. Thus, the formulator
would not have been required to try all
possibilities in a field unreduced by the
prior art. The prior art was not vague in
pointing toward a general approach or
area of exploration, but rather guided
the formulator precisely to the use of
either a normal pill or an enteric-coated
pill.
It is important for Office personnel to
recognize that the mere existence of a
large number of options does not in and
of itself lead to a conclusion of
nonobviousness. Where the prior art
teachings lead one of ordinary skill in
the art to a narrower set of options, then
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
53655
that reduced set is the appropriate one
to consider when determining
obviousness using an obvious to try
rationale.
Example 4.18. Sanofi-Synthelabo v.
Apotex, Inc., 550 F.3d 1075 (Fed. Cir.
2008). Teaching point: A claimed
isolated stereoisomer would not have
been obvious where the claimed
stereoisomer exhibits unexpectedly
strong therapeutic advantages over the
prior art racemic mixture without the
correspondingly expected toxicity, and
the resulting properties of the
enantiomers separated from the racemic
mixture were unpredictable.
The case of Sanofi also sheds light on
the obvious to try line of reasoning. The
claimed compound was clopidogrel,
which is the dextrorotatory isomer of
methyl alpha-5(4,5,6,7-tetrahydro(3,2c)thienopyridyl)(2-chlorophenyl)acetate. Clopidogrel is an antithrombotic compound used to treat or
prevent heart attack or stroke. The
racemate, or mixture of dextrorotatory
and levorotatory (D- and L-) isomers of
the compound, was known in the prior
art. The two forms had not previously
been separated, and although the
mixture was known to have antithrombotic properties, the extent to
which each of the individual isomers
contributed to the observed properties
of the racemate was not known and was
not predictable.
The district court assumed that in the
absence of any additional information,
the D-isomer would have been prima
facie obvious over the known racemate.
However, in view of the evidence of
unpredicted therapeutic advantages of
the D-isomer presented in the case, the
district court found that any prima facie
case of obviousness had been overcome.
At trial, the experts for both parties
testified that persons of ordinary skill in
the art could not have predicted the
degree to which the isomers would have
exhibited different levels of therapeutic
activity and toxicity. Both parties’
experts also agreed that the isomer with
greater therapeutic activity would most
likely have had greater toxicity. Sanofi
witnesses testified that Sanofi’s own
researchers had believed that the
separation of the isomers was unlikely
to have been productive, and experts for
both parties agreed that it was difficult
to separate isomers at the time of the
invention. Nevertheless, when Sanofi
ultimately undertook the task of
separating the isomers, it found that
they had the ‘‘rare characteristic of
‘absolute stereoselectivity,’ ’’ whereby
the D-isomer provided all of the
favorable therapeutic activity but no
significant toxicity, while the L-isomer
produced no therapeutic activity but
E:\FR\FM\01SEN1.SGM
01SEN1
53656
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
hsrobinson on DSK69SOYB1PROD with NOTICES
virtually all of the toxicity. Based on
this record, the district court concluded
that Apotex had not met its burden of
proving by clear and convincing
evidence that Sanofi’s patent was
invalid for obviousness. The Federal
Circuit affirmed the district court’s
conclusion.
Office personnel should recognize
that even when only a small number of
possible choices exist, the obvious to try
line of reasoning is not appropriate
when, upon consideration of all of the
evidence, the outcome would not have
been reasonably predictable and the
inventor would not have had a
reasonable expectation of success. In
Bayer, there were art-based reasons to
expect that both the normal pill and the
enteric-coated pill would be
therapeutically suitable, even though
not all prior art studies were in
complete agreement. Thus, the result
obtained was not unexpected. In Sanofi,
on the other hand, there was strong
evidence that persons of ordinary skill
in the art, prior to the separation of the
isomers, would have had no reason to
expect that the D-isomer would have
such strong therapeutic advantages as
compared with the L-isomer. In other
words, the result in Sanofi was
unexpected.
Example 4.19. Rolls-Royce, PLC v.
United Technologies Corp., 603 F.3d
1325 (Fed. Cir. 2010). Teaching point:
An obvious to try rationale may be
proper when the possible options for
solving a problem were known and
finite. However, if the possible options
were not either known or finite, then an
obvious to try rationale cannot be used
to support a conclusion of obviousness.
In Rolls-Royce the Federal Circuit
addressed the obvious to try rationale in
the context of a fan blade for jet engines.
The case had arisen out of an
interference proceeding. Finding that
the district court had correctly
determined that there was no
interference-in-fact because RollsRoyce’s claims would not have been
obvious in light of United’s application,
the Federal Circuit affirmed.
The Federal Circuit described the fan
blade of the count as follows:
Each fan blade has three regions—an inner,
an intermediate, and an outer region. The
area closest to the axis of rotation at the hub
is the inner region. The area farthest from the
center of the engine and closest to the casing
surrounding the engine is the outer region.
The intermediate region falls in between. The
count defines a fan blade with a sweptforward inner region, a swept-rearward
intermediate region, and forward-leaning
outer region.
Id. at 1328.
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
United had argued that it would have
been obvious for a person of ordinary
skill in the art to try a fan blade design
in which the sweep angle in the outer
region was reversed as compared with
prior art fan blades from rearward to
forward sweep, in order to reduce
endwall shock. The Federal Circuit
disagreed with United’s assessment that
the claimed fan blade would have been
obvious based on an obvious to try
rationale. The Federal Circuit pointed
out that in a proper obvious to try
approach to obviousness, the possible
options for solving a problem must have
been ‘‘known and finite.’’ Id. at 1339,
citing Abbott, 544 F.3d at 1351. In this
case, there had been no suggestion in
the prior art that would have suggested
that changing the sweep angle as RollsRoyce had done would have addressed
the issue of endwall shock. Thus, the
Federal Circuit concluded that changing
the sweep angle ‘‘would not have
presented itself as an option at all, let
alone an option that would have been
obvious to try.’’ Rolls-Royce, 603 F.3d at
1339. The decision in Rolls-Royce is a
reminder to Office personnel that the
obvious to try rationale can properly be
used to support a conclusion of
obviousness only when the claimed
solution would have been selected from
a finite number of potential solutions
known to persons of ordinary skill in
the art.
Example 4.20. Perfect Web
Technologies, Inc. v. InfoUSA, Inc., 587
F.3d 1324, 1328–29 (Fed. Cir. 2009).
Teaching point: Where there were a
finite number of identified, predictable
solutions and there is no evidence of
unexpected results, an obvious to try
inquiry may properly lead to a legal
conclusion of obviousness. Common
sense may be used to support a legal
conclusion of obviousness so long as it
is explained with sufficient reasoning.
The Perfect Web case provides an
example in which the Federal Circuit
held that a claimed method for
managing bulk e-mail distribution was
obvious on the basis of an obvious to try
argument. In Perfect Web, the method
required selecting the intended
recipients, transmitting the e-mails,
determining how many of the e-mails
had been successfully received, and
repeating the first three steps if a predetermined minimum number of
intended recipients had not received the
e-mail.
The Federal Circuit affirmed the
district court’s determination on
summary judgment that the claimed
invention would have been obvious.
Failure to meet a desired quota of e-mail
recipients was a recognized problem in
the field of e-mail marketing. The prior
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
art had also recognized three potential
solutions: Increasing the size of the
initial recipient list; resending e-mails
to recipients who did not receive them
on the first attempt; and selecting a new
recipient list and sending e-mails to
them. The last option corresponded to
the fourth step of the invention as
claimed.
The Federal Circuit noted that based
on ‘‘simple logic,’’ selecting a new list of
recipients was more likely to result in
the desired outcome than resending to
those who had not received the e-mail
on the first attempt. There had been no
evidence of any unexpected result
associated with selecting a new
recipient list, and no evidence that the
method would not have had a
reasonable likelihood of success. Thus,
the Federal Circuit concluded that, as
required by KSR, there were a ‘‘finite
number of identified, predictable
solutions,’’ and that the obvious to try
inquiry properly led to the legal
conclusion of obviousness.
The Federal Circuit in Perfect Web
also discussed the role of common sense
in the determination of obviousness.
The district court had cited KSR for the
proposition that ‘‘[a] person of ordinary
skill is also a person of ordinary
creativity, not an automaton,’’ and found
that ‘‘the final step [of the claimed
invention] is merely the logical result of
common sense application of the maxim
‘try, try again.’ ’’ In affirming the district
court, the Federal Circuit undertook an
extended discussion of common sense
as it has been applied to the
obviousness inquiry, both before and
since the KSR decision.
The Federal Circuit pointed out that
application of common sense is not
really an innovation in the law of
obviousness when it stated, ‘‘Common
sense has long been recognized to
inform the analysis of obviousness if
explained with sufficient reasoning.’’
Perfect Web, 587 F.3d at 1328 (emphasis
added). The Federal Circuit then
provided a review of a number of
precedential cases that inform the
understanding of common sense,
including In re Bozek, 416 F.2d 1385,
1390 (CCPA 1969) (explaining that a
patent examiner may rely on ‘‘common
knowledge and common sense of the
person of ordinary skill in the art
without any specific hint or suggestion
in a particular reference’’) and In re
Zurko, 258 F.3d 1379, 1383, 1385 (Fed.
Cir. 2001) (clarifying that a factual
foundation is needed in order for an
examiner to invoke ‘‘good common
sense’’ in a case in which ‘‘basic
knowledge and common sense was not
based on any evidence in the record’’).
E:\FR\FM\01SEN1.SGM
01SEN1
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
hsrobinson on DSK69SOYB1PROD with NOTICES
The Federal Circuit implicitly
acknowledged in Perfect Web that the
kind of strict evidence-based teaching,
suggestion, or motivation required in In
re Lee, 277 F.3d 1338, 1344 (Fed. Cir.
2002), is not an absolute requirement for
an obviousness rejection in light of the
teachings of KSR. The Federal Circuit
explained that ‘‘[a]t the time [of the Lee
decision], we required the PTO to
identify record evidence of a teaching,
suggestion, or motivation to combine
references.’’ However, Perfect Web went
on to state that even under Lee, common
sense could properly be applied when
analyzing evidence relevant to
obviousness. Citing DyStar Textilfarben
GmbH v. C.H. Patrick Co., 464 F.3d
1356 (Fed. Cir. 2006), and In re Kahn,
441 F.3d 977 (Fed. Cir. 2006), two cases
decided shortly before the Supreme
Court’s decision in KSR, the Federal
Circuit noted that although ‘‘a reasoned
explanation that avoids conclusory
generalizations’’ is required to use
common sense, identification of a
‘‘specific hint or suggestion in a
particular reference’’ is not.
5. Federal Circuit Cases Discussing
Consideration of Evidence. Office
personnel should consider all rebuttal
evidence that is timely presented by the
applicants when reevaluating any
obviousness determination. In the case
of a claim rendered obvious by a
combination of prior art references,
applicants may submit evidence or
argument to demonstrate that the results
of the claimed combination were
unexpected.
Another area that has thus far
remained consistent with pre-KSR
precedent is the consideration of
rebuttal evidence and secondary
considerations in the determination of
obviousness. As reflected in the MPEP,
such evidence should not be considered
simply for its ‘‘knockdown’’ value;
rather, all evidence must be reweighed
to determine whether the claims are
nonobvious.
Once the applicant has presented rebuttal
evidence, Office personnel should reconsider
any initial obviousness determination in
view of the entire record. See, e.g., In re
Piasecki, 745 F.2d 1468, 1472, 223 USPQ
785, 788 (Fed. Cir. 1984); In re Eli Lilly & Co.,
90 F.2d 943, 945, 14 USPQ2d 1741, 1743
(Fed. Cir. 1990). All the rejections of record
and proposed rejections and their bases
should be reviewed to confirm their
continued viability.
MPEP § 2141.
Office personnel should not evaluate
rebuttal evidence for its ‘‘knockdown’’ value
against the prima facie case, Piasecki, 745
F.2d at 1473, 223 USPQ at 788, or summarily
dismiss it as not compelling or insufficient.
If the evidence is deemed insufficient to
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
rebut the prima facie case of obviousness,
Office personnel should specifically set forth
the facts and reasoning that justify this
conclusion.
MPEP § 2145. The following cases
exemplify the continued application of
these principles both at the Federal
Circuit and within the Office. Note that
these principles were at issue in some
of the cases previously discussed, and
have been addressed there in a more
cursory fashion.
Example 5.1. PharmaStem
Therapeutics, Inc. v. Viacell, Inc., 491
F.3d 1342 (Fed. Cir. 2007). Teaching
point: Even though all evidence must be
considered in an obviousness analysis,
evidence of nonobviousness may be
outweighed by contradictory evidence
in the record or by what is in the
specification. Although a reasonable
expectation of success is needed to
support a case of obviousness, absolute
predictability is not required.
The claims at issue in PharmaStem
were directed to compositions
comprising hematopoietic stem cells
from umbilical cord or placental blood,
and to methods of using such
compositions for treatment of blood and
immune system disorders. The
composition claims required that the
stem cells be present in an amount
sufficient to effect hematopoietic
reconstitution when administered to a
human adult. The trial court had found
that PharmaStem’s patents were
infringed and not invalid on
obviousness or other grounds. On
appeal, the Federal Circuit reversed the
district court, determining that the
claims were invalid for obviousness.
The Federal Circuit discussed the
evidence presented at trial. It pointed
out that the patentee, PharmaStem, had
not invented an entirely new procedure
or new composition. Rather,
PharmaStem’s own specification
acknowledged that it was already
known in the prior art that umbilical
cord and placental blood-based
compositions contained hematopoietic
stem cells, and that hematopoietic stem
cells were useful for the purpose of
hematopoietic reconstitution.
PharmaStem’s contribution was to
provide experimental proof that
umbilical cord and placental blood
could be used to effect hematopoietic
reconstitution in mice. By extrapolation,
one of ordinary skill in the art would
have expected this reconstitution
method to work in humans as well.
The court rejected PharmaStem’s
expert testimony that hematopoietic
stem cells had not been proved to exist
in cord blood prior to the experiments
described in PharmaStem’s patents. The
court explained that the expert
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
53657
testimony was contrary to the inventors’
admissions in the specification, as well
as prior art teachings that disclosed
stem cells in cord blood. In this case,
PharmaStem’s evidence of
nonobviousness was outweighed by
contradictory evidence.
Despite PharmaStem’s useful
experimental validation of
hematopoietic reconstitution using
hematopoietic stem cells from umbilical
cord and placental blood, the Federal
Circuit found that the claims at issue
would have been obvious. There had
been ample suggestion in the prior art
that the claimed method would have
worked. Absolute predictability is not a
necessary prerequisite to a case of
obviousness. Rather, a degree of
predictability that one of ordinary skill
would have found to be reasonable is
sufficient. The Federal Circuit
concluded that ‘‘[g]ood science and
useful contributions do not necessarily
result in patentability.’’ Id. at 1364.
Example 5.2. In re Sullivan, 498 F.3d
1345 (Fed. Cir. 2007). Teaching point:
All evidence, including evidence
rebutting a prima facie case of
obviousness, must be considered when
properly presented.
It was found to be an error in Sullivan
for the Board to fail to consider
evidence submitted to rebut a prima
facie case of obviousness.
The claimed invention was directed
to an antivenom composition
comprising F(ab) fragments used to treat
venomous rattlesnake bites. The
composition was created from antibody
molecules that include three fragments,
F(ab)2, F(ab) and F(c), which have
separate properties and utilities. There
have been commercially available
antivenom products that consisted of
whole antibodies and F(ab)2 fragments,
but researchers had not experimented
with antivenoms containing only F(ab)
fragments because it was believed that
their unique properties would prevent
them from decreasing the toxicity of
snake venom. The inventor, Sullivan,
discovered that F(ab) fragments are
effective at neutralizing the lethality of
rattlesnake venom, while reducing the
occurrence of adverse immune reactions
in humans. On appeal of the examiner’s
rejection, the Board held that the claim
was obvious because all the elements of
the claimed composition were
accounted for in the prior art, and that
the composition taught by that prior art
would have been expected by a person
of ordinary skill in the art at the time
the invention was made to neutralize
the lethality of the venom of a
rattlesnake.
Rebuttal evidence had not been
considered by the Board because it
E:\FR\FM\01SEN1.SGM
01SEN1
hsrobinson on DSK69SOYB1PROD with NOTICES
53658
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
considered the evidence to relate to the
intended use of the claimed
composition as an antivenom, rather
than the composition itself. Appellant
successfully argued that even if the
Board had shown a prima facie case of
obviousness, the extensive rebuttal
evidence must be considered. The
evidence included three expert
declarations submitted to show that the
prior art taught away from the claimed
invention, an unexpected property or
result from the use of F(ab) fragment
antivenom, and why those having
ordinary skill in the art expected
antivenoms comprising F(ab) fragments
to fail. The declarations related to more
than the use of the claimed
composition. While a statement of
intended use may not render a known
composition patentable, the claimed
composition was not known, and
whether it would have been obvious
depends upon consideration of the
rebuttal evidence. Appellant did not
concede that the only distinguishing
factor of its composition is the statement
of intended use and extensively argued
that its claimed composition exhibits
the unexpected property of neutralizing
the lethality of rattlesnake venom while
reducing the occurrence of adverse
immune reactions in humans. The
Federal Circuit found that such a use
and unexpected property cannot be
ignored—the unexpected property is
relevant and thus the declarations
describing it should have been
considered.
Nonobviousness can be shown when
a person of ordinary skill in the art
would not have reasonably predicted
the claimed invention based on the
prior art, and the resulting invention
would not have been expected. All
evidence must be considered when
properly presented.
Example 5.3. Hearing Components,
Inc. v. Shure Inc., 600 F.3d 1357 (Fed.
Cir. 2010). Teaching point: Evidence
that has been properly presented in a
timely manner must be considered on
the record. Evidence of commercial
success is pertinent where a nexus
between the success of the product and
the claimed invention has been
demonstrated.
The case of Hearing Components
involved a disposable protective
covering for the portion of a hearing aid
that is inserted into the ear canal. The
covering was such that it could be
readily replaced by a user as needed.
At the district court, Shure had
argued that Hearing Components’
patents were obvious over one or more
of three different combinations of prior
art references. The jury disagreed, and
determined that the claims were
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
nonobvious. The district court upheld
the jury verdict, stating that in view of
the conflicting evidence presented by
the parties as to the teachings of the
references, motivation to combine, and
secondary considerations, the
nonobviousness verdict was sufficiently
grounded in the evidence.
Shure appealed to the Federal Circuit,
but the Federal Circuit agreed with the
district court that the jury’s
nonobviousness verdict had been
supported by substantial evidence.
Although Shure had argued before the
jury that the Carlisle reference taught an
ear piece positioned inside the ear
canal, Hearing Components’ credible
witness countered that only the molded
duct and not the ear piece itself was
taught by Carlisle as being inside the ear
canal. On the issue of combining
references, Shure’s witness had given
testimony described as ‘‘rather sparse,
and lacking in specific details.’’ Id. at
1364. In contradistinction, Hearing
Components’ witness ‘‘described
particular reasons why one skilled in
the art would not have been motivated
to combine the references.’’ Id. Finally,
as to secondary considerations, the
Federal Circuit determined that Hearing
Components had shown a nexus
between the commercial success of its
product and the patent by providing
evidence that ‘‘the licensing fee for a
covered product was more than cut in
half immediately upon expiration’’ of
the patent.
Although the Hearing Components
case involves substantial evidence of
nonobviousness in a jury verdict, it is
nevertheless instructive for Office
personnel on the matter of weighing
evidence. Office personnel routinely
must consider evidence in the form of
prior art references, statements in the
specification, or declarations under 37
CFR 1.131 or 1.132. Other forms of
evidence may also be presented during
prosecution. Office personnel are
reminded that evidence that has been
presented in a timely manner should
not be ignored, but rather should be
considered on the record. However, not
all evidence need be accorded the same
weight. In determining the relative
weight to accord to rebuttal evidence,
considerations such as whether a nexus
exists between the claimed invention
and the proffered evidence, and whether
the evidence is commensurate in scope
with the claimed invention, are
appropriate. The mere presence of some
credible rebuttal evidence does not
dictate that an obviousness rejection
must always be withdrawn. See MPEP
§ 2145. Office personnel must consider
the appropriate weight to be accorded to
each piece of evidence. An obviousness
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
rejection should be made or maintained
only if evidence of obviousness
outweighs evidence of nonobviousness.
See MPEP § 706(I) (‘‘The standard to be
applied in all cases is the
‘preponderance of the evidence’ test. In
other words, an examiner should reject
a claim if, in view of the prior art and
evidence of record, it is more likely than
not that the claim is unpatentable.’’).
MPEP § 716.01(d) provides further
guidance on weighing evidence in
making a determination of patentability.
Example 5.4. Asyst Techs., Inc. v.
Emtrak, Inc., 544 F.3d 1310 (Fed. Cir.
2008). Teaching point: Evidence of
secondary considerations of
obviousness such as commercial success
and long-felt need may be insufficient to
overcome a prima facie case of
obviousness if the prima facie case is
strong. An argument for nonobviousness
based on commercial success or longfelt need is undermined when there is
a failure to link the commercial success
or long-felt need to a claimed feature
that distinguishes over the prior art.
The claims at issue in Asyst
concerned a processing system for
tracking articles such as silicon wafers
which move from one processing station
to the next in a manufacturing facility.
The claims required that each
processing station be in communication
with a central control unit. The Federal
Circuit agreed with the district court
that the only difference between the
claimed invention and the prior art to
Hesser was that the prior art had taught
the use of a bus for this communication,
while the claims required a multiplexer.
At trial, the jury had concluded that
Hesser was not relevant prior art, but
the district court overturned that
conclusion and issued a judgment as a
matter of law (JMOL) that the claims
would have been obvious in view of
Hesser. Because the evidence showed
that persons of ordinary skill in the art
would have been familiar with both the
bus and the multiplexer, and that they
could have readily selected and
employed one or the other based on
known considerations, the Federal
Circuit affirmed the district court’s
conclusion that the claims were invalid
for obviousness.
The Federal Circuit also discussed
arguments that the district court had
failed to consider the objective evidence
of nonobviousness presented by Asyst.
Asyst had offered evidence of
commercial success of its invention.
However, the Federal Circuit pointed
out that Asyst had not provided the
required nexus between the commercial
success and the claimed invention,
emphasizing that ‘‘Asyst’s failure to link
that commercial success to the features
E:\FR\FM\01SEN1.SGM
01SEN1
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
of its invention that were not disclosed
in Hesser undermines the probative
force of the evidence * * *.’’ Id. at 1316.
Asyst had also offered evidence from
others in the field praising the invention
as addressing a long-felt need. Once
again, the Federal Circuit found the
argument to be unavailing in view of the
prior art, stating that ‘‘[w]hile the
evidence shows that the overall system
drew praise as a solution to a felt need,
there was no evidence that the success
* * * was attributable to the
substitution of a multiplexer for a bus,
which was the only material difference
between Hesser and the patented
invention.’’ Id. The Federal Circuit also
reiterated, citing pre-KSR decisions, that
‘‘as we have often held, evidence of
secondary considerations does not
always overcome a strong prima facie
showing of obviousness.’’ Id. (citing
Pfizer, Inc. v. Apotex, Inc., 480 F.3d
1348, 1372 (Fed. Cir. 2007); Ryko Mfg.
Co. v. Nu-Star, Inc., 950 F.2d 714, 719–
20 (Fed. Cir. 1991); Newell Cos. v.
Kenney Mfg. Co., 864 F.2d 757, 768
(Fed. Cir. 1988)).
When considering obviousness, Office
personnel should carefully weigh any
properly presented objective evidence of
nonobviousness against the strength of
the prima facie case. If the asserted
evidence, such as commercial success or
satisfaction of a long-felt need, is
attributable to features already in the
prior art, the probative value of the
evidence is reduced.
6. Conclusion. This 2010 KSR
Guidelines Update is intended to be
used by Office personnel in conjunction
with the guidance provided in MPEP
§§ 2141 and 2143 (which incorporates
the 2007 KSR Guidelines) to clarify the
contours of obviousness after KSR. It
Case
53659
addresses a number of issues that arise
when Office personnel consider
whether or not a claimed invention is
obvious. While Office personnel are
encouraged to make use of these tools,
they are reminded that every question of
obviousness must be decided on its own
facts. The Office will continue to
monitor the developing law of
obviousness, and will provide
additional guidance and updates as
necessary.
Dated: August 20, 2010.
David J. Kappos,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
Appendix
The following table contains the cases set
out as examples in this 2010 KSR Guidelines
Update and the teaching points of the case.
Teaching point
Combining Prior Art Elements
In re Omeprazole Patent Litigation,
536 F.3d 1361 (Fed. Cir. 2008).
Crocs, Inc. v. U.S. Int’l Trade
Comm’n., 598 F.3d 1294 (Fed.
Cir. 2010).
Sundance, Inc. v. DeMonte Fabricating Ltd., 550 F.3d 1356 (Fed.
Cir. 2008).
Ecolab, Inc. v. FMC Corp., 569
F.3d 1335 (Fed. Cir. 2009).
Wyers v. Master Lock
2009–1412, —F.3d—,
2901839 (Fed. Cir.
2010).
DePuy Spine, Inc. v.
Sofamor Danek, Inc.,
1314 (Fed. Cir. 2009).
Co., No.
2010 WL
July 22,
Medtronic
567 F.3d
Even where a general method that could have been applied to make the claimed product was known and
within the level of skill of the ordinary artisan, the claim may nevertheless be nonobvious if the problem
which had suggested use of the method had been previously unknown.
A claimed combination of prior art elements may be nonobvious where the prior art teaches away from the
claimed combination and the combination yields more than predictable results.
A claimed invention is likely to be obvious if it is a combination of known prior art elements that would reasonably have been expected to maintain their respective properties or functions after they have been
combined.
A combination of known elements would have been prima facie obvious if an ordinarily skilled artisan
would have recognized an apparent reason to combine those elements and would have known how to
do so.
The scope of analogous art is to be construed broadly and includes references that are reasonably pertinent to the problem that the inventor was trying to solve. Common sense may be used to support a
legal conclusion of obviousness so long as it is explained with sufficient reasoning.
Predictability as discussed in KSR encompasses the expectation that prior art elements are capable of
being combined, as well as the expectation that the combination would have worked for its intended purpose. An inference that a claimed combination would not have been obvious is especially strong where
the prior art’s teachings undermine the very reason being proffered as to why a person of ordinary skill
would have combined the known elements.
Substituting One Known Element for Another
In re ICON Health & Fitness, Inc.,
496 F.3d 1374 (Fed. Cir. 2007).
Agrizap, Inc. v. Woodstream Corp.,
520 F.3d 1337 (Fed. Cir. 2008).
hsrobinson on DSK69SOYB1PROD with NOTICES
Muniauction, Inc. v. Thomson
Corp., 532 F.3d 1318 (Fed. Cir.
2008).
Aventis Pharma Deutschland v.
Lupin, Ltd., 499 F.3d 1293 (Fed.
Cir. 2007).
Eisai Co. Ltd. v. Dr. Reddy’s Labs.,
Ltd., 533 F.3d 1353 (Fed. Cir.
2008).
Procter & Gamble Co. v. Teva
Pharmaceuticals USA, Inc., 566
F.3d 989 (Fed. Cir. 2009).
VerDate Mar<15>2010
18:24 Aug 31, 2010
When determining whether a reference in a different field of endeavor may be used to support a case of
obviousness (i.e., is analogous), it is necessary to consider the problem to be solved.
Analogous art is not limited to references in the field of endeavor of the invention, but also includes references that would have been recognized by those of ordinary skill in the art as useful for applicant’s
purpose.
Because Internet and Web browser technologies had become commonplace for communicating and displaying information, it would have been obvious to adapt existing processes to incorporate them for
those functions.
A chemical compound would have been obvious over a mixture containing that compound as well as other
compounds where it was known or the skilled artisan had reason to believe that some desirable property
of the mixture was derived in whole or in part from the claimed compound, and separating the claimed
compound from the mixture was routine in the art.
A claimed compound would not have been obvious where there was no reason to modify the closest prior
art lead compound to obtain the claimed compound and the prior art taught that modifying the lead compound would destroy its advantageous property. Any known compound may serve as a lead compound
when there is some reason for starting with that lead compound and modifying it to obtain the claimed
compound.
It is not necessary to select a single compound as a ‘‘lead compound’’ in order to support an obviousness
rejection. However, where there was reason to select and modify the lead compound to obtain the
claimed compound, but no reasonable expectation of success, the claimed compound would not have
been obvious.
Jkt 220001
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
E:\FR\FM\01SEN1.SGM
01SEN1
53660
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
Case
Teaching point
Altana Pharma AG v. Teva
Pharms. USA, Inc., 566 F.3d 999
(Fed. Cir. 2009).
Obviousness of a chemical compound in view of its structural similarity to a prior art compound may be
shown by identifying some line of reasoning that would have led one of ordinary skill in the art to select
and modify a prior art lead compound in a particular way to produce the claimed compound. It is not
necessary for the reasoning to be explicitly found in the prior art of record, nor is it necessary for the
prior art to point to only a single lead compound.
The Obvious To Try Rationale
In re Kubin, 561 F.3d 1351 (Fed.
Cir. 2009).
Takeda
Chem.
Indus.
v.
Alphapharm Pty., Ltd., 492 F.3d
1350 (Fed. Cir. 2007).
Ortho-McNeil Pharmaceutical, Inc.
v. Mylan Labs, Inc., 520 F.3d
1358 (Fed. Cir. 2008).
Bayer Schering Pharma A.G. v.
Barr Labs., Inc., 575 F.3d 1341
(Fed. Cir. 2009).
Sanofi-Synthelabo v. Apotex, Inc.,
550 F.3d 1075 (Fed. Cir. 2008).
Rolls-Royce, PLC v. United Technologies Corp., 603 F.3d 1325
(Fed. Cir. 2010).
Perfect Web Techs., Inc. v.
InfoUSA, Inc., 587 F.3d 1324
(Fed. Cir. 2009).
A claimed polynucleotide would have been obvious over the known protein that it encodes where the
skilled artisan would have had a reasonable expectation of success in deriving the claimed
polynucleotide using standard biochemical techniques, and the skilled artisan would have had a reason
to try to isolate the claimed polynucleotide. KSR applies to all technologies, rather than just the ‘‘predictable’’ arts.
A claimed compound would not have been obvious where it was not obvious to try to obtain it from a
broad range of compounds, any one of which could have been selected as the lead compound for further investigation, and the prior art taught away from using a particular lead compound, and there was
no predictability or reasonable expectation of success in making the particular modifications necessary
to transform the lead compound into the claimed compound.
Where the claimed anti-convulsant drug had been discovered somewhat serendipitously in the course of
research aimed at finding a new anti-diabetic drug, it would not have been obvious to try to obtain a
claimed compound where the prior art did not present a finite and easily traversed number of potential
starting compounds, and there was no apparent reason for selecting a particular starting compound from
among a number of unpredictable alternatives.
A claimed compound would have been obvious where it was obvious to try to obtain it from a finite and
easily traversed number of options that was narrowed down from a larger set of possibilities by the prior
art, and the outcome of obtaining the claimed compound was reasonably predictable.
A claimed isolated stereoisomer would not have been obvious where the claimed stereoisomer exhibits unexpectedly strong therapeutic advantages over the prior art racemic mixture without the correspondingly
expected toxicity, and the resulting properties of the enantiomers separated from the racemic mixture
were unpredictable.
An obvious to try rationale may be proper when the possible options for solving a problem were known
and finite. However, if the possible options were not either known or finite, then an obvious to try rationale cannot be used to support a conclusion of obviousness.
Where there were a finite number of identified, predictable solutions and there is no evidence of unexpected results, an obvious to try inquiry may properly lead to a legal conclusion of obviousness. Common sense may be used to support a legal conclusion of obviousness so long as it is explained with sufficient reasoning.
Consideration of Evidence
PharmaStem Therapeutics, Inc. v.
ViaCell, Inc., 491 F.3d 1342
(Fed. Cir. 2007).
In re Sullivan, 498 F.3d 1345 (Fed.
Cir. 2007).
Hearing Components, Inc. v. Shure
Inc., 600 F.3d 1357 (Fed. Cir.
2010).
Asyst Techs., Inc. v. Emtrak, Inc.,
544 F.3d 1310 (Fed. Cir. 2008).
Even though all evidence must be considered in an obviousness analysis, evidence of nonobviousness
may be outweighed by contradictory evidence in the record or by what is in the specification. Although a
reasonable expectation of success is needed to support a case of obviousness, absolute predictability is
not required.
All evidence, including evidence rebutting a prima facie case of obviousness, must be considered when
properly presented.
Evidence that has been properly presented in a timely manner must be considered on the record. Evidence of commercial success is pertinent where a nexus between the success of the product and the
claimed invention has been demonstrated.
Evidence of secondary considerations of obviousness such as commercial success and long-felt need may
be insufficient to overcome a prima facie case of obviousness if the prima facie case is strong. An argument for nonobviousness based on commercial success or long-felt need is undermined when there is a
failure to link the commercial success or long-felt need to a claimed feature that distinguishes over the
prior art.
[FR Doc. 2010–21646 Filed 8–31–10; 8:45 am]
hsrobinson on DSK69SOYB1PROD with NOTICES
BILLING CODE P
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
PO 00000
Frm 00031
Fmt 4703
Sfmt 9990
E:\FR\FM\01SEN1.SGM
01SEN1
Agencies
[Federal Register Volume 75, Number 169 (Wednesday, September 1, 2010)]
[Notices]
[Pages 53643-53660]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-21646]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No.: PTO-P-2010-0055]
Examination Guidelines Update: Developments in the Obviousness
Inquiry After KSR v.Teleflex
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office (USPTO or
Office) is issuing an update (2010 KSR Guidelines Update) to its
obviousness guidelines for its personnel to be used when applying the
law of obviousness under
[[Page 53644]]
35 U.S.C. 103. This 2010 KSR Guidelines Update highlights case law
developments on obviousness under 35 U.S.C. 103 since the 2007 decision
by the United States Supreme Court (Supreme Court) in KSR Int'l Co. v.
Teleflex Inc. These guidelines are intended to be used by Office
personnel in conjunction with the guidance in the Manual of Patent
Examining Procedure when applying the law of obviousness under 35
U.S.C. 103. Members of the public are invited to provide comments on
the 2010 KSR Guidelines Update. The Office is especially interested in
receiving suggestions of recent decisional law in the field of
obviousness that would have particular value as teaching tools.
DATES: Effective Date: This 2010 KSR Guidelines Update is effective
September 1, 2010.
ADDRESSES: Comments concerning this 2010 KSR Guidelines Update may be
sent by electronic mail message over the Internet addressed to KSR_Guidance@uspto.gov, or submitted by mail addressed to: Mail Stop
Comments--Patents, Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450. Although comments may be submitted by mail, the Office
prefers to receive comments via the Internet.
FOR FURTHER INFORMATION CONTACT: Kathleen Kahler Fonda or Pinchus M.
Laufer, Legal Advisors, Office of Patent Legal Administration, Office
of the Associate Commissioner for Patent Examination Policy, by
telephone at (571) 272-7754 or (571) 272-7726; by mail addressed to:
Mail Stop Comments Patents, Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450; or by facsimile transmission to (571) 273-
7754, marked to the attention of Kathleen Kahler Fonda.
SUPPLEMENTARY INFORMATION:
1. Introduction. The purpose of this 2010 KSR Guidelines Update is
to remind Office personnel of the principles of obviousness explained
by the Supreme Court in KSR Int'l Co. v. Teleflex Inc., 550 U.S 398
(2007) (KSR), and to provide additional guidance in view of decisions
by the United States Court of Appeals for the Federal Circuit (Federal
Circuit) since KSR. This body of case law developed over the past three
years provides additional examples that will be useful to Office
personnel as well as practitioners during the examination process.
Although every question of obviousness must be decided on its own
facts, these cases begin to clarify the contours of the obviousness
inquiry after KSR, and help to show when a rejection on this basis is
proper and when it is not.
This 2010 KSR Guidelines Update does not constitute substantive
rule making and hence does not have the force and effect of law. It has
been developed as a matter of internal Office management and is not
intended to create any right or benefit, substantive or procedural,
enforceable by any party against the Office. Rejections will continue
to be based upon the substantive law, and it is these rejections that
are appealable. Consequently, any failure by Office personnel to follow
this 2010 KSR Guidelines Update is neither appealable nor petitionable.
After a review of the principles of obviousness and Office policy
as reflected in the Manual of Patent Examining Procedure (MPEP), this
2010 KSR Guidelines Update addresses a number of issues that arise when
Office personnel consider whether or not a claimed invention is
obvious. The concepts discussed are grounded in Federal Circuit cases,
and correlated with existing Office policy as appropriate. A number of
cases which have been selected for their instructional value on the
issue of obviousness will be discussed in detail.
The law of obviousness will continue to be refined, and Office
personnel are encouraged to maintain an awareness of precedential case
law from the Federal Circuit and precedential decisions of the Board of
Patent Appeals and Interferences (Board) in this area. The Office will
train Office personnel and update the MPEP as necessary to reflect the
current state of the law.
2. Principles of Obviousness and the Guidelines. In response to the
Supreme Court's April 2007 decision in KSR, the Office developed
guidelines for patent examiners to follow when determining obviousness
of a claimed invention and published these guidelines in the Federal
Register and Official Gazette. See Examination Guidelines for
Determining Obviousness Under 35 U.S.C. 103 in View of the Supreme
Court Decision in KSR International Co. v. Teleflex Inc., 72 FR 57526
(Oct. 10, 2007), 1324 Off. Gaz. Pat. Office 23 (Nov. 6, 2007) (2007 KSR
Guidelines). The 2007 KSR Guidelines have been incorporated in the
MPEP. See MPEP Sec. 2141 (8th ed. 2001) (Rev. 6, Sept. 2007). The
purpose of the 2007 KSR Guidelines was to give Office personnel
practical guidance on how to evaluate obviousness issues under 35
U.S.C. 103(a) in accordance with the Supreme Court's instruction in
KSR. The 2007 KSR Guidelines also alerted Office personnel to the
importance of considering rebuttal evidence submitted by patent
applicants in response to obviousness rejections.
The 2007 KSR Guidelines pointed out, as had the Supreme Court in
KSR, that the factual inquiries announced in Graham v. John Deere, 383
U.S. 1, 17-18 (1966) (scope and content of the prior art; differences
between the claimed invention and the prior art; level of ordinary
skill in the art; and secondary indicia of nonobviousness), remain the
foundation of any determination of obviousness. It remains true that
``[t]he determination of obviousness is dependent on the facts of each
case.'' Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075, 1089 (Fed.
Cir. 2008) (citing Graham, 383 U.S. at 17-18 (1966)). As for the
reasoning required to support an obviousness determination, the 2007
KSR Guidelines noted that the teaching-suggestion-motivation (TSM) test
was but one possible approach. The 2007 KSR Guidelines identified six
other rationales gleaned from the KSR decision as examples of
appropriate lines of reasoning that could also be used. The six other
rationales identified in the 2007 KSR Guidelines are: (1) Combining
prior art elements according to known methods to yield predictable
results; (2) simple substitution of one known element for another to
obtain predictable results; (3) use of a known technique to improve
similar devices, methods, or products in the same way; (4) applying a
known technique to a known device, method, or product ready for
improvement to yield predictable results; (5) obvious to try--choosing
from a finite number of identified, predictable solutions, with a
reasonable expectation of success; and (6) known work in one field of
endeavor may prompt variations of it for use in either the same field
or a different one based on design incentives or other market forces if
the variations are predictable to one of ordinary skill in the art. Any
rationale employed must provide a link between the factual findings and
the legal conclusion of obviousness.
It is important for Office personnel to recognize that when they do
choose to formulate an obviousness rejection using one of the
rationales suggested by the Supreme Court in KSR and discussed in the
2007 KSR Guidelines, they are to adhere to the instructions provided in
the MPEP regarding the necessary factual findings. However, the 2007
KSR Guidelines also stressed that while the Graham inquiries and the
associated reasoning are crucial to a proper obviousness determination,
the Supreme Court in KSR did not place any limit on the particular
approach to be taken to formulate the line of reasoning.
[[Page 53645]]
In other words, the KSR decision is not to be seen as replacing a
single test for obviousness--the TSM test--with the seven rationales
listed in the 2007 KSR Guidelines. See MPEP Sec. Sec. 2141 and 2143
(8th ed. 2001) (Rev. 8, July 2010) (references to the MPEP are to
Revision 8 of the 8th Edition of the MPEP unless otherwise indicated).
It remains Office policy that appropriate factual findings are required
in order to apply the enumerated rationales properly. If a rejection
has been made that omits one of the required factual findings, and in
response to the rejection a practitioner or inventor points out the
omission, Office personnel must either withdraw the rejection, or
repeat the rejection including all required factual findings.
3. The Impact of the KSR Decision. KSR's renewed emphasis on the
foundational principles of Graham coupled with its abrogation of the
strict TSM test have clearly impacted the manner in which Office
personnel and practitioners carry out the business of prosecuting
patent applications with regard to issues of obviousness. However,
Office personnel as well as practitioners should also recognize the
significant extent to which the obviousness inquiry has remained
constant in the aftermath of KSR.
In footnote 2 of the 2007 KSR Guidelines, the Office acknowledged
that ongoing developments in the law of obviousness were to be expected
in the wake of the KSR decision. That footnote also stated that it was
``not clear which Federal Circuit decisions will retain their
viability'' after KSR. See 2007 KSR Guidelines, 72 FR at 57,528 n.2.
The edition of the MPEP that was current when the KSR decision was
handed down had made the following statement in Sec. 2144:
The rationale to modify or combine the prior art does not have
to be expressly stated in the prior art; the rationale may be
expressly or impliedly contained in the prior art or it may be
reasoned from knowledge generally available to one of ordinary skill
in the art, established scientific principles, or legal precedent
established by prior case law.
MPEP Sec. 2144 (8th ed. 2001) (Rev. 5, Aug. 2006) (citing five
pre-KSR Federal Circuit opinions and two decisions of the Board). The
KSR decision has reinforced those earlier decisions that validated a
more flexible approach to providing reasons for obviousness. However,
the Supreme Court's pronouncement in KSR has at the same time clearly
undermined the continued viability of cases such as In re Lee, 277 F.3d
1338 (Fed. Cir. 2002), insofar as Lee appears to require a strict basis
in record evidence as a reason to modify the prior art.
The Supreme Court's flexible approach to the obviousness inquiry is
reflected in numerous pre-KSR decisions, as can be seen in a review of
MPEP Sec. 2144. This section provides many lines of reasoning to
support a determination of obviousness based upon earlier legal
precedent that had condoned the use of particular examples of what may
be considered common sense or ordinary routine practice (e.g., making
integral, changes in shape, making adjustable). Thus, the type of
reasoning sanctioned by the opinion in KSR has long been a part of the
patent examination process. See MPEP Sec. 2144.
Although the KSR approach is flexible with regard to the line of
reasoning to be applied, the 2007 KSR Guidelines and MPEP Sec. 2143
state: ``The Supreme Court in KSR noted that the analysis supporting a
rejection under 35 U.S.C. 103 should be made explicit.'' MPEP Sec.
2143. In Ball Aerosol v. Limited Brands, 555 F.3d 984 (Fed. Cir. 2009),
the Federal Circuit offered additional instruction as to the need for
an explicit analysis. The Federal Circuit explained, as is consistent
with the 2007 KSR Guidelines, that the Supreme Court's requirement for
an explicit analysis does not require record evidence of an explicit
teaching of a motivation to combine in the prior art.
[T]he analysis that ``should be made explicit'' refers not to
the teachings in the prior art of a motivation to combine, but to
the court's analysis * * *. Under the flexible inquiry set forth by
the Supreme Court, the district court therefore erred by failing to
take account of ``the inferences and creative steps,'' or even
routine steps, that an inventor would employ and by failing to find
a motivation to combine related pieces from the prior art.
Ball Aerosol, 555 F.3d at 993. The Federal Circuit's directive in
Ball Aerosol was addressed to a lower court, but it applies to Office
personnel as well. When setting forth a rejection, Office personnel are
to continue to make appropriate findings of fact as explained in MPEP
Sec. Sec. 2141 and 2143, and must provide a reasoned explanation as to
why the invention as claimed would have been obvious to a person of
ordinary skill in the art at the time of the invention. This
requirement for explanation remains even in situations in which Office
personnel may properly rely on intangible realities such as common
sense and ordinary ingenuity.
When considering obviousness, Office personnel are cautioned
against treating any line of reasoning as a per se rule. MPEP Sec.
2144 discusses supporting a rejection under 35 U.S.C. 103 by reliance
on scientific theory and legal precedent. In keeping with the flexible
approach and the requirement for explanation, Office personnel may
invoke legal precedent as a source of supporting rationale when
warranted and appropriately supported. See MPEP Sec. 2144.04. So, for
example, automating a manual activity, making portable, making
separable, reversal or duplication of parts, or purifying an old
product may form the basis of a rejection. However, such rationales
should not be treated as per se rules, but rather must be explained and
shown to apply to the facts at hand. A similar caveat applies to any
obviousness analysis. Simply stating the principle (e.g., ``art
recognized equivalent,'' ``structural similarity'') without providing
an explanation of its applicability to the facts of the case at hand is
generally not sufficient to establish a prima facie case of
obviousness.
Many basic approaches that a practitioner may use to demonstrate
nonobviousness also continue to apply in the post-KSR era. Since it is
now clear that a strict TSM approach is not the only way to establish a
prima facie case of obviousness, it is true that practitioners have
been required to shift the emphasis of their nonobviousness arguments
to a certain degree. However, familiar lines of argument still apply,
including teaching away from the claimed invention by the prior art,
lack of a reasonable expectation of success, and unexpected results.
Indeed, they may have even taken on added importance in view of the
recognition in KSR of a variety of possible rationales.
At the time the KSR decision was handed down, some observers
questioned whether the principles discussed were intended by the
Supreme Court to apply to all fields of inventive endeavor. Arguments
were made that because the technology at issue in KSR involved the
relatively well-developed and predictable field of vehicle pedal
assemblies, the decision was relevant only to such fields. The Federal
Circuit has soundly repudiated such a notion, stating that KSR applies
across technologies:
This court also declines to cabin KSR to the ``predictable
arts'' (as opposed to the ``unpredictable art'' of biotechnology).
In fact, this record shows that one of skill in this advanced art
would find these claimed ``results'' profoundly ``predictable.''
In re Kubin, 561 F.3d 1351, 1360 (Fed. Cir. 2009). Thus, Office
personnel should not withdraw any rejection solely on the basis that
the invention lies in a technological area ordinarily considered to be
unpredictable.
The decisions of the Federal Circuit discussed in this 2010 KSR
Guidelines
[[Page 53646]]
Update provide Office personnel as well as practitioners with
additional examples of the law of obviousness. The purpose of the 2007
KSR Guidelines was, as stated above, to help Office personnel to
determine when a claimed invention is not obvious, and to provide an
appropriate supporting rationale when an obviousness rejection is
appropriate. Now that a body of case law is available to guide Office
personnel and practitioners as to the boundaries between obviousness
and nonobviousness, it is possible in this 2010 KSR Guidelines Update
to contrast situations in which the subject matter was found to have
been obvious with those in which it was determined not to have been
obvious. Thus, Office personnel may use this 2010 KSR Guidelines Update
in conjunction with the 2007 KSR Guidelines (incorporated into MPEP
Sec. Sec. 2141 and 2143) to provide a more complete view of the state
of the law of obviousness.
This 2010 KSR Guidelines Update provides a ``teaching point'' for
each discussed case. The ``teaching point'' may be used to quickly
determine the relevance of the discussed case, but should not be used
as a substitute for reading the remainder of the discussion of the case
in this 2010 KSR Guidelines Update. Nor should any case in this 2010
KSR Guidelines Update be applied or cited in an Office action solely on
the basis of what is stated in the ``teaching point'' for the case.
4. Obviousness Examples from Federal Circuit Cases. The impact of
the Supreme Court's decision in KSR can be more readily understood in
the context of factual scenarios. The cases in this 2010 KSR Guidelines
Update are broadly grouped according to obviousness concepts in order
to provide persons involved with patent prosecution with ready access
to the examples that are most pertinent to the issue at hand. The first
three groups correspond directly with three of the rationales
identified in the 2007 KSR Guidelines. These rationales--combining
prior art elements, substituting one known element for another, and
obvious to try--have each been the subject of a significant number of
post-KSR obviousness decisions. The fourth group focuses on issues
concerning consideration of evidence during prosecution. Office
personnel as well as practitioners are reminded of the technology-
specific obviousness examples previously posted on the Office's Web
site at https://www.uspto.gov/web/offices/pac/dapp/opla/ksr/ksr_training_materials.htm.
Although the other rationales discussed in the 2007 KSR Guidelines
are not the focus of separate discussions in this 2010 KSR Guidelines
Update, it will be noted that obviousness concepts such as applying
known techniques, design choice, and market forces are addressed when
they arise in the selected cases. The cases included in this 2010 KSR
Guidelines Update reinforce the idea, presented in the 2007 KSR
Guidelines, that there may be more than one line of reasoning that can
properly be applied to a particular factual scenario. The selected
decisions also illustrate the overlapping nature of the lines of
reasoning that may be employed to establish a prima facie case of
obviousness. Although the 2007 KSR Guidelines presented the rationales
as discrete, self-contained lines of reasoning, and they may indeed be
employed that way, it is useful to recognize that real-world situations
may require analyses that may not be so readily pigeon-holed into
distinct categories.
A. Combining Prior Art Elements. In discussing the obviousness
rationale concerning combining prior art elements, identified as
Rationale A, the 2007 KSR Guidelines quoted KSR and noted that ``it can
be important to identify a reason that would have prompted a person of
ordinary skill in the relevant field to combine the elements in the way
the claimed new invention does.'' KSR, 550 U.S. at 401. In view of the
cases decided since KSR, one situation when it is important to identify
a reason to combine known elements in a known manner to obtain
predictable results is when the combination requires a greater
expenditure of time, effort, or resources than the prior art teachings.
Even though the components are known, the combining step is technically
feasible, and the result is predictable, the claimed invention may
nevertheless be nonobvious when the combining step involves such
additional effort that no one of ordinary skill would have undertaken
it without a recognized reason to do so. When a combination invention
involves additional complexity as compared with the prior art, the
invention may be nonobvious unless an examiner can articulate a reason
for including the added features or steps. This is so even when the
claimed invention could have been readily implemented.
Example 4.1. In re Omeprazole Patent Litigation, 536 F.3d 1361
(Fed. Cir. 2008). Teaching point: Even where a general method that
could have been applied to make the claimed product was known and
within the level of skill of the ordinary artisan, the claim may
nevertheless be nonobvious if the problem which had suggested use of
the method had been previously unknown.
The case of In re Omeprazole Patent Litigation is one in which the
claims in question were found to be nonobvious in the context of an
argument to combine prior art elements. The invention involved applying
enteric coatings to a drug in pill form for the purpose of ensuring
that the drug did not disintegrate before reaching its intended site of
action. The drug at issue was omeprazole, the generic name for gastric
acid inhibitor marketed as Prilosec[reg]. The claimed formulation
included two layers of coatings over the active ingredient.
The district court found that Astra's patent in suit was infringed
by defendants Apotex and Impax. The district court rejected Apotex's
defense that the patents were invalid for obviousness. Apotex had
argued that the claimed invention was obvious because coated omeprazole
tablets were known from a prior art reference, and because secondary
subcoatings in pharmaceutical preparations generally were also known.
There was no evidence of unpredictability associated with applying two
different enteric coatings to omeprazole. However, Astra's reason for
applying an intervening subcoating between the prior art coating and
omeprazole had been that the prior art coating was actually interacting
with omeprazole, thereby contributing to undesirable degradation of the
active ingredient. This degradation of omeprazole by interaction with
the prior art coating had not been recognized in the prior art.
Therefore, the district court reasoned that based on the evidence
available, a person of ordinary skill in the art would have had no
reason to include a subcoating in an omeprazole pill formulation.
The Federal Circuit affirmed the district court's decision that the
claimed invention was not obvious. Even though subcoatings for enteric
drug formulation were known, and there was no evidence of undue
technical hurdles or lack of a reasonable expectation of success, the
formulation was nevertheless not obvious because the flaws in the prior
art formulation that had prompted the modification had not been
recognized. Thus there would have been no reason to modify the initial
formulation, even though the modification could have been done.
Moreover, a person of skill in the art likely would have chosen a
different modification even if he or she had recognized the problem.
Office personnel should note that in this case the modification of
the prior art that had been presented as an
[[Page 53647]]
argument for obviousness was an extra process step that added an
additional component to a known, successfully marketed formulation. The
proposed modification thus amounted to extra work and greater expense
for no apparent reason. This is not the same as combining known prior
art elements A and B when each would have been expected to contribute
its own known properties to the final product. In the Omeprazole case,
in view of the expectations of those of ordinary skill in the art,
adding the subcoating would not have been expected to confer any
particular desirable property on the final product. Rather, the final
product obtained according to the proposed modifications would merely
have been expected to have the same functional properties as the prior
art product.
The Omeprazole case can also be analyzed in view of the discovery
of a previously unknown problem by the patentee. If the adverse
interaction between active agent and coating had been known, it might
well have been obvious to use a subcoating. However, since the problem
had not been previously known, there would have been no reason to incur
additional time and expense to add another layer, even though the
addition would have been technologically possible. This is true because
the prior art of record failed to mention any stability problem,
despite the acknowledgment during testimony at trial that there was a
known theoretical reason that omeprazole might be subject to
degradation in the presence of the known coating material.
Example 4.2. Crocs, Inc. v. U.S. International Trade Commission,
598 F.3d 1294 (Fed. Cir. 2010). Teaching point: A claimed combination
of prior art elements may be nonobvious where the prior art teaches
away from the claimed combination and the combination yields more than
predictable results.
The case of Crocs, Inc. v. U.S. International Trade Commission is a
decision in which the claimed foam footwear was held by the Federal
Circuit to be nonobvious over a combination of prior art references.
The claims involved in the obviousness issue were from Crocs' U.S.
Patent No. 6,993,858, and were drawn to footwear in which a one-piece
molded foam base section formed the top of the shoe (the upper) and the
sole. A strap also made of foam was attached to the foot opening of the
upper, such that the strap could provide support to the Achilles
portion of the wearer's foot. The strap was attached via connectors
that allowed it to be in contact with the base section, and to pivot
relative to the base section. Because both the base portion and the
strap were made of foam, friction between the strap and the base
section allowed the strap to maintain its position after pivoting. In
other words, the foam strap did not fall under the force of gravity to
a position adjacent to the heel of the base section.
The International Trade Commission (ITC) determined that the claims
were obvious over the combination of two pieces of prior art. The first
was the Aqua Clog, which was a shoe that corresponded to the base
section of the footwear of the `858 patent. The second was the Aguerre
patent, which taught heel straps made of elastic or another flexible
material. In the ITC's view, the claimed invention was obvious because
the prior art Aqua Clog differed from the claimed invention only as to
the presence of the strap, and a suitable strap was taught by Aguerre.
The Federal Circuit disagreed. The Federal Circuit stated that the
prior art did not teach foam heel straps, or that a foam heel strap
should be placed in contact with a foam base. The Federal Circuit
pointed out that the prior art actually counseled against using foam as
a material for the heel strap of a shoe.
The record shows that the prior art would actually discourage
and teach away from the use of foam straps. An ordinary artisan in
this field would not add a foam strap to the foam Aqua Clog because
foam was likely to stretch and deform, in addition to causing
discomfort for a wearer. The prior art depicts foam as unsuitable
for straps.
Id. at 1309.
The Federal Circuit continued, stating that even if--contrary to
fact--the claimed invention had been a combination of elements that
were known in the prior art, the claims still would have been
nonobvious. There was testimony in the record that the loose fit of the
heel strap made the shoe more comfortable for the wearer than prior art
shoes in which the heel strap was constantly in contact with the
wearer's foot. In the claimed footwear, the foam heel strap contacted
the wearer's foot only when needed to help reposition the foot properly
in the shoe, thus reducing wearer discomfort that could arise from
constant contact. This desirable feature was a result of the friction
between the base section and the strap that kept the strap in place
behind the Achilles portion of the wearer's foot. The Federal Circuit
pointed out that this combination ``yielded more than predictable
results.'' Id. at 1310. Aguerre had taught that friction between the
base section and the strap was a problem rather than an advantage, and
had suggested the use of nylon washers to reduce friction. Thus the
Federal Circuit stated that even if all elements of the claimed
invention had been taught by the prior art, the claims would not have
been obvious because the combination yielded more than predictable
results.
The Federal Circuit's discussion in Crocs serves as a reminder to
Office personnel that merely pointing to the presence of all claim
elements in the prior art is not a complete statement of a rejection
for obviousness. In accordance with MPEP Sec. 2143 A(3), a proper
rejection based on the rationale that the claimed invention is a
combination of prior art elements also includes a finding that results
flowing from the combination would have been predictable to a person of
ordinary skill in the art. MPEP Sec. 2143 A(3). If results would not
have been predictable, Office personnel should not enter an obviousness
rejection using the combination of prior art elements rationale, and
should withdraw such a rejection if it has been made.
Example 4.3. Sundance, Inc. v. DeMonte Fabricating Ltd., 550 F.3d
1356 (Fed. Cir. 2008). Teaching point: A claimed invention is likely to
be obvious if it is a combination of known prior art elements that
would reasonably have been expected to maintain their respective
properties or functions after they have been combined.
Sundance involved a segmented and mechanized cover for trucks,
swimming pools, or other structures. The claim was found to be obvious
over the prior art applied.
A first prior art reference taught that a reason for making a
segmented cover was ease of repair, in that a single damaged segment
could be readily removed and replaced when necessary. A second prior
art reference taught the advantages of a mechanized cover for ease of
opening. The Federal Circuit noted that the segmentation aspect of the
first reference and the mechanization function of the second perform in
the same way after combination as they had before. The Federal Circuit
further observed that a person of ordinary skill in the art would have
expected that adding replaceable segments as taught by the first
reference to the mechanized cover of the other would result in a cover
that maintained the advantageous properties of both of the prior art
covers.
Thus, the Sundance case points out that a hallmark of a proper
obviousness rejection based on combining known prior art elements is
that one of ordinary skill in the art would reasonably have expected
the elements to maintain their respective properties or functions after
they have been combined.
[[Page 53648]]
Example 4.4. Ecolab, Inc. v. FMC Corp., 569 F.3d 1335 (Fed Cir.
2009). Teaching point: A combination of known elements would have been
prima facie obvious if an ordinarily skilled artisan would have
recognized an apparent reason to combine those elements and would have
known how to do so.
In the case of Ecolab, Inc. v. FMC Corp., an ``apparent reason to
combine'' in conjunction with the technical ability to optimize led to
the conclusion that the claimed invention would have been obvious.
The invention in question was a method of treating meat to reduce
the incidence of pathogens, by spraying the meat with an antibacterial
solution under specified conditions. The parties did not dispute that a
single prior art reference had taught all of the elements of the
claimed invention, except for the pressure limitation of ``at least 50
psi.''
FMC had argued at the district court that the claimed invention
would have been obvious in view of the first prior art reference
mentioned above in view of a second reference that had taught the
advantages of spray-treating at pressures of 20 to 150 psi when
treating meat with a different antibacterial agent. The district court
did not find FMC's argument to be convincing, and denied the motion for
judgment as a matter of law that the claim was obvious.
Disagreeing with the district court, the Federal Circuit stated
that ``there was an apparent reason to combine these known elements--
namely to increase contact between the [antibacterial solution] and the
bacteria on the meat surface and to use the pressure to wash additional
bacteria off the meat surface.'' Id. at 1350. The Federal Circuit
explained that because the second reference had taught ``using high
pressure to improve the effectiveness of an antimicrobial solution when
sprayed onto meat, and because an ordinarily skilled artisan would have
recognized the reasons for applying [the claimed antibacterial
solution] using high pressure and would have known how to do so,
Ecolab's claims combining high pressure with other limitations
disclosed in FMC's patent are invalid as obvious.'' Id.
When considering the question of obviousness, Office personnel
should keep in mind the capabilities of a person of ordinary skill. In
Ecolab, the Federal Circuit stated:
Ecolab's expert admitted that one skilled in the art would know
how to adjust application parameters to determine the optimum
parameters for a particular solution. The question then is whether
it would have been obvious to combine the high pressure parameter
disclosed in the Bender patent with the PAA methods disclosed in
FMC's `676 patent. The answer is yes.
Id. If optimization of the application parameters had not been within
the level of ordinary skill in the art, the outcome of the Ecolab case
may well have been different.
Example 4.5. Wyers v. Master Lock Co., No. 2009-1412, --F.3d--,
2010 WL 2901839 (Fed. Cir. July 22, 2010). Teaching point: The scope of
analogous art is to be construed broadly and includes references that
are reasonably pertinent to the problem that the inventor was trying to
solve. Common sense may be used to support a legal conclusion of
obviousness so long as it is explained with sufficient reasoning.
In the case of Wyers v. Master Lock Co., the Federal Circuit held
that the claimed barbell-shaped hitch pin locks used to secure trailers
to vehicles were obvious.
The court discussed two different sets of claims in Wyers, both
drawn to improvements over the prior art hitch pin locks. The first
improvement was a removable sleeve that could be placed over the shank
of the hitch pin lock so that the same lock could be used with towing
apertures of varying sizes. The second improvement was an external flat
flange seal adapted to protect the internal lock mechanism from
contaminants. Wyers had admitted that each of several prior art
references taught every element of the claimed inventions except for
the removable sleeve and the external covering. Master Lock had argued
that these references, in combination with additional references
teaching the missing elements, would have rendered the claims obvious.
The court first addressed the question of whether the additional
references relied on by Master Lock were analogous prior art. As to the
reference teaching the sleeve improvement, the court concluded that it
dealt specifically with using a vehicle to tow a trailer, and was
therefore in the same field of endeavor as Wyers' sleeve improvement.
The reference teaching the sealing improvement dealt with a padlock
rather than a lock for a tow hitch. The court noted that Wyers'
specification had characterized the claimed invention as being in the
field of locking devices, thus at least suggesting that the sealed
padlock reference was in the same field of endeavor. However, the court
also observed that even if sealed padlocks were not in the same field
of endeavor, they were nevertheless reasonably pertinent to the problem
of avoiding contamination of a locking mechanism for tow hitches. The
court explained that the Supreme Court's decision in KSR ``directs [it]
to construe the scope of analogous art broadly.'' Wyers, slip. op. at
12. For these reasons, the court found that Master Lock's asserted
references were analogous prior art, and therefore relevant to the
obviousness inquiry.
The court then turned to the question of whether there would have
been adequate motivation to combine the prior art elements as had been
urged by Master Lock. The court recalled the Graham inquiries, and also
emphasized the ``expansive and flexible'' post-KSR approach to
obviousness that must not ``deny factfinders recourse to common
sense.'' Wyers, slip op. at 13 (quoting KSR, 550 U.S. at 415 and 421).
The court stated:
KSR and our later cases establish that the legal determination
of obviousness may include recourse to logic, judgment, and common
sense, in lieu of expert testimony * * *.
Thus, in appropriate cases, the ultimate inference as to the
existence of a motivation to combine references may boil down to a
question of ``common sense,'' appropriate for resolution on summary
judgment or JMOL.
Id. at 15 (citing Perfect Web Techs., Inc. v. InfoUSA, Inc., 587 F.3d
1324, 1329 (Fed. Cir. 2009); Ball Aerosol, 555 F.3d at 993).
After reviewing these principles, the court proceeded to explain
why adequate motivation to combine had been established in this case.
With regard to the sleeve improvement, it pointed out that the need for
different sizes of hitch pins was well known in the art, and that this
was a known source of inconvenience and expense for users. The court
also mentioned the marketplace aspect of the issue, noting that space
on store shelves was at a premium, and that removable sleeves addressed
this economic concern. As to the sealing improvement, the court pointed
out that both internal and external seals were well-known means to
protect locks from contaminants. The court concluded that the
constituent elements were being employed in accordance with their
recognized functions, and would have predictably retained their
respective functions when combined as suggested by Master Lock. The
court cited In re O'Farrell, 853 F.2d 894, 904 (Fed. Cir. 1988) for the
proposition that a reasonable expectation of success is a requirement
for a proper determination of obviousness.
Office personnel should note that although the Federal Circuit
invoked the idea of common sense in support of a conclusion of
obviousness, it did not end its explanation there. Rather, the
[[Page 53649]]
court explained why a person of ordinary skill in the art at the time
of the invention, in view of the facts relevant to the case, would have
found the claimed inventions to have been obvious. As stated in the
MPEP:
The key to supporting any rejection under 35 U.S.C. 103 is the
clear articulation of the reason(s) why the claimed invention would
have been obvious. The Supreme Court in KSR noted that the analysis
supporting a rejection under 35 U.S.C. 103 should be made explicit.
The Court quoting In re Kahn, 441 F.3d 977, 988, 78 USPQ2d 1329,
1336 (Fed. Cir. 2006), stated that ``[R]ejections on obviousness
cannot be sustained by mere conclusory statements; instead, there
must be some articulated reasoning with some rational underpinning
to support the legal conclusion of obviousness.''
MPEP Sec. 2141 III. Office personnel should continue to provide a
reasoned explanation for every obviousness rejection.
Example 4.6. DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc.,
567 F.3d 1314 (Fed. Cir. 2009). Teaching point: Predictability as
discussed in KSR encompasses the expectation that prior art elements
are capable of being combined, as well as the expectation that the
combination would have worked for its intended purpose. An inference
that a claimed combination would not have been obvious is especially
strong where the prior art's teachings undermine the very reason being
proffered as to why a person of ordinary skill would have combined the
known elements.
The claim in DePuy Spine was directed to a polyaxial pedicle screw
used in spinal surgeries that included a compression member for
pressing a screw head against a receiver member. A prior art reference
(Puno) disclosed all of the elements of the claim except for the
compression member. Instead, the screw head in Puno was separated from
the receiver member to achieve a shock absorber effect, allowing some
motion between receiver member and the vertebrae. The missing
compression member was readily found in another prior art reference
(Anderson), which disclosed an external fracture immobilization splint
for immobilizing long bones with a swivel clamp capable of polyaxial
movement until rigidly secured by a compression member. It was asserted
during trial that a person of ordinary skill would have recognized that
the addition of Anderson's compression member to Puno's device would
have achieved a rigidly locked polyaxial pedicle screw covered by the
claim.
In conducting its analysis, the Federal Circuit noted that the
``predictable result'' discussed in KSR refers not only to the
expectation that prior art elements are capable of being physically
combined, but also that the combination would have worked for its
intended purpose. In this case, it was successfully argued that Puno
``teaches away'' from a rigid screw because Puno warned that rigidity
increases the likelihood that the screw will fail within the human
body, rendering the device inoperative for its intended purpose. In
fact, the reference did not merely express a general preference for
pedicle screws having a ``shock absorber'' effect, but rather expressed
concern for failure and stated that the shock absorber feature
``decrease[s] the chance of failure of the screw of the bone-screw
interface'' because ``it prevent[s] direct transfer of load from the
rod to the bone-screw interface.'' Thus, the alleged reason to combine
the prior art elements of Puno and Anderson--increasing the rigidity of
the screw--ran contrary to the prior art that taught that increasing
rigidity would result in a greater likelihood of failure. In view of
this teaching and the backdrop of collective teachings of the prior
art, the Federal Circuit determined that Puno teaches away from the
proposed combination such that a person of ordinary skill would have
been deterred from combining the references as proposed. Secondary
considerations evaluated by the Federal Circuit relating to failure by
others and copying also supported the view that the combination would
not have been obvious at the time of the invention.
B. Substituting One Known Element for Another. As explained in the
2007 KSR Guidelines, the substitution rationale applies when the
claimed invention can be viewed as resulting from substituting a known
element for an element of a prior art invention. The rationale applies
when one of ordinary skill in the art would have been technologically
capable of making the substitution, and the result obtained would have
been predictable. See MPEP Sec. 2143(B).
Example 4.7. In re ICON Health & Fitness, Inc., 496 F.3d 1374 (Fed.
Cir. 2007). Teaching point: When determining whether a reference in a
different field of endeavor may be used to support a case of
obviousness (i.e., is analogous), it is necessary to consider the
problem to be solved.
The claimed invention in ICON was directed to a treadmill with a
folding tread base that swivels into an upright storage position,
including a gas spring connected between the tread base and the upright
structure to assist in stably retaining the tread base in the storage
position. On reexamination, the examiner rejected the claims as obvious
based on a combination of references including an advertisement
(Damark) for a folding treadmill demonstrating all of the claim
elements other than the gas spring, and a patent (Teague) with a gas
spring. Teague was directed to a bed that folds into a cabinet using a
novel dual-action spring that reverses force as the mechanism passes a
neutral position, rather than a single-action spring that would provide
a force pushing the bed closed at all times. The dual-action spring
reduced the force required to open the bed from the closed position,
while reducing the force required to lift the bed from the open
position.
The Federal Circuit addressed the propriety of making the
combination since Teague comes from a different field than the
application. Teague was found to be reasonably pertinent to the problem
addressed in the application because the folding mechanism did not
require any particular focus on treadmills, but rather generally
addressed problems of supporting the weight of such a mechanism and
providing a stable resting position.
Other evidence was considered concerning whether one skilled in the
art would have been led to combine the teachings of Damark and Teague.
Appellant argued that Teague teaches away from the invention because it
directs one skilled in the art not to use single-action springs and
does not satisfy the claim limitations as the dual-action springs would
render the invention inoperable. The Federal Circuit considered the
arguments and found that while Teague at most teaches away from using
single-action springs to decrease the opening force, it actually
instructed that single-action springs provide the result desired by the
inventors, which was to increase the opening force provided by gravity.
As to inoperability, the claims were not limited to single-action
springs and were so broad as to encompass anything that assists in
stably retaining the tread base, which is the function that Teague
accomplished. Additionally, the fact that the counterweight mechanism
from Teague used a large spring, which appellant argued would overpower
the treadmill mechanism, ignores the modifications that one skilled in
the art would make to a device borrowed from the prior art. One skilled
in the art would size the components from Teague appropriately for the
application.
ICON is another useful example for understanding the scope of
analogous art. The art applied concerned retaining mechanisms for
folding beds, not treadmills. When determining whether a
[[Page 53650]]
reference may properly be applied to an invention in a different field
of endeavor, it is necessary to consider the problem to be solved. It
is certainly possible that a reference may be drawn in such a way that
its usefulness as a teaching is narrowly restricted. However, in ICON,
the ``treadmill'' concept was too narrow a lens through which to view
the art in light of the prior art teachings concerning the problem to
be solved. The Teague reference was analogous art because ``Teague and
the current application both address the need to stably retain a
folding mechanism,'' id. at 1378, and because ``nothing about ICON's
folding mechanism requires any particular focus on treadmills,'' id. at
1380.
ICON is also informative as to the relationship between the problem
to be solved and existence of a reason to combine. ``Indeed, while
perhaps not dispositive of the issue, the finding that Teague, by
addressing a similar problem, provides analogous art to ICON's
application goes a long way towards demonstrating a reason to combine
the two references. Because ICON's broad claims read on embodiments
addressing that problem as described by Teague, the prior art here
indicates a reason to incorporate its teachings.'' Id. at 1380-81.
The Federal Circuit's discussion in ICON also makes clear that if
the reference does not teach that a combination is undesirable, then it
cannot be said to teach away. An assessment of whether a combination
would render the device inoperable must not ``ignore the modifications
that one skilled in the art would make to a device borrowed from the
prior art.'' Id. at 1382.
Example 4.8. Agrizap, Inc. v. Woodstream Corp., 520 F.3d 1337 (Fed.
Cir. 2008). Teaching point: Analogous art is not limited to references
in the field of endeavor of the invention, but also includes references
that would have been recognized by those of ordinary skill in the art
as useful for applicant's purpose.
Agrizap involved a stationary pest control device for electrocution
of pests such as rats and gophers, in which the device is set in an
area where the pest is likely to encounter it. The only difference
between the claimed device and the prior art stationary pest control
device was that the claimed device employed a resistive electrical
switch, while the prior art device used a mechanical pressure switch. A
resistive electrical switch was taught in two prior art patents, in the
contexts of a hand-held pest control device and a cattle prod.
In determining that the claimed invention was obvious, the Federal
Circuit noted that ``[t]he asserted claims simply substitute a
resistive electrical switch for the mechanical pressure switch''
employed in the prior art device. Id. at 1344. In this case, the prior
art concerning the hand-held devices revealed that the function of the
substituted resistive electrical switch was well known and predictable,
and that it could be used in a pest control device. According to the
Federal Circuit, the references that taught the hand-held devices
showed that ``the use of an animal body as a resistive switch to
complete a circuit for the generation of an electric charge was already
well known in the prior art.'' Id. Finally, the Federal Circuit noted
that the problem solved by using the resistive electrical switch in the
prior art hand-held devices--malfunction of mechanical switches due to
dirt and dampness--also pertained to the prior art stationary pest
control device.
The Federal Circuit recognized Agrizap as ``a textbook case of when
the asserted claims involve a combination of familiar elements
according to known methods that does no more than yield predictable
results.'' Id. Agrizap exemplifies a strong case of obviousness based
on simple substitution that was not overcome by the objective evidence
of nonobviousness offered. It also demonstrates that analogous art is
not limited to the field of applicant's endeavor, in that one of the
references that used an animal body as a resistive switch to complete a
circuit for the generation of an electric charge was not in the field
of pest control.
Example 4.9. Muniauction, Inc. v. Thomson Corp., 532 F.3d 1318
(Fed. Cir. 2008). Teaching point: Because Internet and Web browser
technologies had become commonplace for communicating and displaying
information, it would have been obvious to adapt existing processes to
incorporate them for those functions.
The invention at issue in Muniauction was a method for auctioning
municipal bonds over the Internet. A municipality could offer a package
of bond instruments of varying principal amounts and maturity dates,
and an interested buyer would then submit a bid comprising a price and
interest rate for each maturity date. It was also possible for the
interested buyer to bid on a portion of the offering. The claimed
invention considered all of the noted parameters to determine the best
bid. It operated on conventional Web browsers and allowed participants
to monitor the course of the auction.
The only difference between the prior art bidding system and the
claimed invention was the use of a conventional Web browser. At trial,
the district court had determined that Muniauction's claims were not
obvious. Thomson argued that the claimed invention amounted to
incorporating a Web browser into a prior art auction system, and was
therefore obvious in light of KSR. Muniauction rebutted the argument by
offering evidence of skepticism by experts, copying, praise, and
commercial success. Although the district court found the evidence to
be persuasive of nonobviousness, the Federal Circuit disagreed. It
noted that a nexus between the claimed invention and the proffered
evidence was lacking because the evidence was not coextensive with the
claims at issue. For this reason, the Federal Circuit determined that
Muniauction's evidence of secondary considerations was not entitled to
substantial weight.
The Federal Circuit analogized this case to Leapfrog Enterprises,
Inc. v. Fisher-Price, Inc., 485 F.3d 1157 (Fed. Cir. 2007), cited in
the 2007 KSR Guidelines. The Leapfrog case involved a determination of
obviousness based on application of modern electronics to a prior art
mechanical children's learning device. In Leapfrog, the court had noted
that market pressures would have prompted a person of ordinary skill to
use modern electronics in the prior art device. Similarly in
Muniauction, market pressures would have prompted a person of ordinary
skill to use a conventional Web browser in a method of auctioning
municipal bonds.
Example 4.10. Aventis Pharma Deutschland v. Lupin Ltd., 499 F.3d
1293 (Fed. Cir. 2007). Teaching point: A chemical compound would have
been obvious over a mixture containing that compound as well as other
compounds where it was known or the skilled artisan had reason to
believe that some desirable property of the mixture was derived in
whole or in part from the claimed compound, and separating the claimed
compound from the mixture was routine in the art.
In Aventis, the claims were drawn to the 5(S) stereoisomer of the
blood pressure drug ramipril in stereochemically pure form, and to
compositions and methods requiring 5(S) ramipril. The 5(S) stereoisomer
is one in which all five stereocenters in the ramipril molecule are in
the S rather than the R configuration. A mixture of various
stereoisomers including 5(S) ramipril had been taught by the prior art.
The question before the court was whether the purified single
stereoisomer
[[Page 53651]]
would have been obvious over the known mixture of stereoisomers.
The record showed that the presence of multiple S stereocenters in
drugs similar to ramipril was known to be associated with enhanced
therapeutic efficacy. For example, when all of the stereocenters were
in the S form in the related drug enalapril (SSS enalapril) as compared
with only two stereocenters in the S form (SSR enalapril), the
therapeutic potency was 700 times as great. There was also evidence to
indicate that conventional methods could be used to separate the
various stereoisomers of ramipril.
The district court saw the issue as a close case, because, in its
view, there was no clear motivation in the prior art to isolate 5(S)
ramipril. However, the Federal Circuit disagreed, and found that the
claims would have been obvious. The Federal Circuit cautioned that
requiring such a clearly stated motivation in the prior art to isolate
5(S) ramipril ran counter to the Supreme Court's decision in KSR. The
court stated:
Requiring an explicit teaching to purify the 5(S) stereoisomer
from a mixture in which it is the active ingredient is precisely the
sort of rigid application of the TSM test that was criticized in
KSR.
Id. at 1301. The Aventis court also relied on the settled principle
that in chemical cases, structural similarity can provide the necessary
reason to modify prior art teachings. The Federal Circuit also
addressed the kind of teaching that would be sufficient in the absence
of an explicitly stated prior art-based motivation, explaining that an
expectation of similar properties in light of the prior art can be
sufficient, even without an explicit teaching that the compound will
have a particular utility.
In the chemical arts, the cases involving so-called ``lead
compounds'' form an important subgroup of the obviousness cases that
are based on substitution. The Federal Circuit has had a number of
opportunities since the KSR decision to discuss the circumstances under
which it would have been obvious to modify a known compound to arrive
at a claimed compound. The following cases explore the selection of a
lead compound, the need to provide a reason for any proposed
modification, and the predictability of the result.
Example 4.11. Eisai Co. Ltd. v. Dr. Reddy's Labs., Ltd., 533 F.3d
1353 (Fed. Cir. 2008). Teaching point: A claimed compound would not
have been obvious where there was no reason to modify the closest prior
art lead compound to obtain the claimed compound and the prior art
taught that modifying the lead compound would destroy its advantageous
property. Any known compound may serve as a lead compound when there is
some reason for starting with that lead compound and modifying it to
obtain the claimed compound.
Eisai concerns the pharmaceutical compound rabeprazole. Rabeprazole
is a proton pump inhibitor for treating stomach ulcers and related
disorders. The Federal Circuit affirmed the district court's summary
judgment of nonobviousness, stating that no reason had been advanced to
modify the prior art compound in a way that would destroy an
advantageous property.
Co-defendant Teva based its obviousness argument on the structural
similarity between rabeprazole and lansoprazole. The compounds were
recognized as sharing a common core, and the Federal Circuit
characterized lansoprazole as a ``lead compound.'' The prior art
compound lansoprazole was useful for the same indications as
rabeprazole, and differed from rabeprazole only in that lansoprazole
has a trifluoroethoxy substituent at the 4-position of the pyridine
ring, while rabeprazole has a methoxypropoxy substituent. The trifluoro
substituent of lansoprazole was known to be a beneficial feature
because it conferred lipophilicity to the compound. The ability of a
person of ordinary skill to carry out the modification to introduce the
methoxypropoxy substituent, and the predictability of the result were
not addressed.
Despite the significant similarity between the structures, the
Federal Circuit did not find any sufficient reason to modify the lead
compound. According to the Federal Circuit:
Obviousness based on structural similarity thus can be proved by
identification of some motivation that would have led one of
ordinary skill in the art to select and then modify a known compound
(i.e. a lead compound) in a particular way to achieve the claimed
compound. * * * In keeping with the flexible nature of the
obviousness inquiry, KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398,
127 S.Ct. 1727, 1739, 167 L.Ed.2d 705 (2007), the requisite
motivation can come from any number of sources and need not
necessarily be explicit in the art. See Aventis Pharma Deutschland
GmbH v. Lupin, Ltd., 499 F.3d 1293, 1301 (Fed. Cir. 2007). Rather
``it is sufficient to show that the claimed and prior art compounds
possess a `sufficiently close relationship * * * to create an
expectation,' in light of the totality of the prior art, that the
new compound will have `similar properties' to the old.'' Id.
(quoting Dillon, 919 F.2d at 692).
Eisai, 533 F.3d at 1357. The prior art taught that introducing a
fluorinated substituent was known to increase lipophilicity, so a
skilled artisan would have expected that replacing the trifluoroethoxy
substituent with a methoxypropoxy substituent would have reduced the
lipophilicity of the compound. Thus, the prior art created the
expectation that rabeprazole would be less useful than lansoprazole as
a drug for treating stomach ulcers and related disorders because the
proposed modification would have destroyed an advantageous property of
the prior art compound. The compound was not obvious as argued by Teva
because, upon consideration of all of the facts of the case, a person
of ordinary skill in the art at the time of the invention would not
have had a reason to modify lansoprazole so as to form rabeprazole.
Office personnel are cautioned that the term ``lead compound'' in a
particular opinion can have a contextual meaning that may vary from the
way a pharmaceutical chemist might use the term. In the field of
pharmaceutical chemistry, the term ``lead compound'' has been defined
variously as ``a chemical compound that has pharmacological or
biological activity and whose chemical structure is used as a starting
point for chemical modifications in order to improve potency,
selectivity, or pharmacokinetic parameters;'' ``[a] compound that
exhibits pharmacological properties which suggest its development;''
and ``a potential drug being tested for safety and efficacy.'' See,
e.g.,https://en.wikipedia.org/wiki/Lead_compound, accessed January 13,
2010; https://www.combichemistry.com/glossary_k.html, accessed January
13, 2010; and https://www.buildingbiotechnology.com/glossary4.php,
accessed January 13, 2010.
The Federal Circuit in Eisai makes it clear that from the
perspective of the law of obviousness, any known compound might
possibly serve as a lead compound: ``Obviousness based on structural
similarity thus can be proved by identification of some motivation that
would have led one of ordinary skill in the art to select and then
modify a known compound (i.e. a lead compound) in a particular way to
achieve the claimed compound.'' Eisai, 533 F.3d at 1357. Thus, Office
personnel should recognize that a proper obviousness rejection of a
claimed compound that is useful as a drug might be made beginning with
an inactive compound, if, for example, the reasons for modifying a
prior art compound to arrive at the claimed compound have nothing to do
with pharmaceutical activity. The inactive compound would not be
considered to be a lead
[[Page 53652]]
compound by pharmaceutical chemists, but could potentially be used as
such when considering obviousness. Office personnel might also base an
obviousness rejection on a known compound that pharmaceutical chemists
would not select as a lead compound due to expense, handling issues, or
other business considerations. However, there must be some reason for
starting with that lead compound other than the mere fact that the
``lead compound'' merely exists. See Altana Pharma AG v. Teva
Pharmaceuticals USA, Inc., 566 F.3d 999, 1007 (Fed. Cir. 2009) (holding
that there must be some reason ``to select and modify a known
compound''); Ortho-McNeil Pharmaceutical, Inc. v. Mylan Labs, Inc., 520
F.3d 1358, 1364 (Fed. Cir. 2008).
Example 4.12. Procter & Gamble Co. v. Teva Pharmaceuticals USA,
Inc., 566 F.3d 989 (Fed. Cir. 2009). Teaching point: It is not
necessary to select a single compound as a ``lead compound'' in order
to support an obviousness rejection. However, where there was reason to
select and modify the lead compound to obtain the claimed compound, but
no reasonable expectation of success, the claimed compound would not
have been obvious.
A chemical compound was also found to be nonobvious in Procter &
Gamble. The compound at issue was risedronate--the active ingredient of
Procter & Gamble's osteoporosis drug Actonel[reg]. Risedronate is an
example of a bisphosphonate, which is a class of compounds known to
inhibit bone resorption.
When Procter & Gamble sued Teva for infringement, Teva defended by
arguing invalidity for obviousness over one of Procter & Gamble's
earlier patents. The prior art patent did not teach risedronate, but
instead taught thirty-six other similar compounds including 2-pyr EHDP
that were potentially useful with regard to osteoporosis. Teva argued
obviousness on the basis of structural similarity to 2-pyr EHDP, which
is a positional isomer of risedronate.
The district court found no reason to select 2-pyr EHDP as a lead
compound in light of the unpredictable nature of the art, and no reason
to modify it so as to obtain risedronate. In addition, there were
unexpected results as t